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ABSTRACT 
Introduction: The worldwide escalation in the incidence of obesity and its strong association 
with insulin resistance, type 2 diabetes and the cardiovascular complications that accompany 
these disease states have elicited interest in the underlying mechanisms of these pathologies. 
Preliminary data generated in our laboratory showed that obesity is associated with 
abnormalities in the insulin signalling pathway. Specifically, we found a down-regulation of 
protein kinase B (PKB/Akt), which is known to mediate the metabolic effects of insulin. One 
of the downstream targets of PKB/Akt is glycogen synthase kinase-3 (GSK-3), which is 
inhibited by this phosphorylation. Detrimental effects of unopposed activity of GSK-3 have 
recently been described. This may play a pivotal role in some of the adverse consequences of 
insulin resistance in the heart.  
Hypothesis: Chronic inhibition of GSK-3 will induce myocardial hypertrophy or exacerbate 
the development of existing hypertrophy in a pre-diabetic model of diet induced obesity and 
insulin resistance. 
Objectives: (1) Assess the extent of the development of myocardial hypertrophy in a rat 
model of diet induced obesity (DIO) and insulin resistance. (2) Assess the effect of inhibition 
of GSK-3 protein on the development of myocardial hypertrophy.  
Methods: Two groups of age-matched male Wistar rats were used. Control animals received 
standard rat chow, while obese animals received a high caloric diet for 20 weeks. After 12 
weeks, half of the animals in both groups received GSK-3 inhibitor treatment (CHIR118637, 
30mg/kg/day, Novartis). At the end of 20 weeks, three series of experiments were conducted. 
(i) The animals were subjected to echocardiography to determine in vivo myocardial function, 
and biometric, metabolic and biochemical parameters were evaluated.  
  
Stellenbosch University http://scholar.sun.ac.za
II	  
(ii) The ability of the cardiomyocytes to accumulate deoxy-glucose after stimulation with 
insulin was determined, and (iii) the localization of key proteins was monitored using 
fluorescence microscopy and cell size was determined using light microscopy and flow 
activated cell sorter analysis. 
Results and discussion: The high caloric diet increased body weight (p<0.005) and intra-
peritoneal fat mass (p<0.01) when compared to controls. Complications associated with 
obesity, such as impaired glucose tolerance (p<0.05), hyperinsulinemia (p<0.0005) and an 
increased HOMA-IR index (p<0.01) were observed. Additionally, cardiomyocytes from the 
DIO animals had a significantly impaired response to insulin, specifically when 10nM 
(p<0.05) and 100nM (p<0.05) of insulin were used as stimulus. We also found a 
dysregulation in PKB/Akt, indicated by a down-regulation of phosphorylated PKB/Akt 
(p<0.01). The diet promoted the development of myocardial hypertrophy, since the 
ventricular weight (p<0.05) and ventricular weight to tibia length ratio were increased 
(p<0.01). Echocardiography experiments showed an increase in end diastolic diameter in the 
DIO animals (p<0.05). Additionally, there was an increase in the cardiomyocyte cell width in 
the DIO rats (p<0.0001) and a tendency for peri-nuclear localization of NFATc3. GSK-3 
inhibition promoted the development of insulin resistance in control animals, as indicated by 
an increase in the body weight (p<0.05), serum insulin levels (p<0.01) and HOMA-IR index 
(p<0.01). In the DIO animals, the GSK-3 inhibitor treatment improved insulin resistance, as a 
decrease in serum insulin concentration (p<0.05) was observed. The cardiomyocytes from the 
treated DIO animals also showed an increase in glucose uptake (p<0.05) when stimulated 
with 100nM of insulin. The GSK-3 inhibitor promoted the development of myocardial 
hypertrophy in the control animals, indicated by an increase in ventricular weight (p<0.05) 
and cardiomyocyte cell width (p<0.0001), but did not exacerbate hypertrophy in the DIO 
animals. 
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Conclusion: Both the high caloric diet and the GSK-3 inhibitor promoted the development of 
insulin resistance and myocardial hypertrophy in the rats. In the DIO animals the GSK-3 
inhibitor treatment ameliorated insulin resistance and did not promote the further 
development of myocardial hypertrophy.  
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OPSOMMING 
Inleiding: Die huidige styging in vetsugtigheid en die sterk assosiasie daarvan met insulien 
weerstandigheid, tipe 2 diabetes en kardiovaskulêre komplikasies soos hipertrofie, het ‘n 
belangstelling in die onderliggende meganismes van hierdie siektetoestande ontlok. 
Voorlopige data uit ons laboratorium het getoon dat vetsug geassosieerd is met abnormaliteite 
in die insulien seintransduksie-pad soos byvoorbeeld ‘n afregulering van miokardiale proteïen 
kinase B (PKB/Akt), wat bekend is om die metaboliese effekte van insulien te medieer. Een 
van die proteïene wat deur PKB/Akt gefosforileer en daardeur geïnhibeer word, is glikogeen 
sintase kinase-3 (GSK-3). Negatiewe effekte van onge-opponeerde aktiwiteit van GSK-3 is 
beskryf en dit mag ‘n sleutelrol speel in sommige van die nadelige gevolge van insulien 
weerstandigheid in die hart.  
Hipotese: Chroniese onderdrukking van GSK-3 sal miokardiale hipertrofie ontlok of die 
bestaande hipertrofie in ‘n pre-diabetiese model van dieet-geïnduseerde vetsug en insulien 
weerstandigheid vererger. 
Doelstellings: (1) Om die omvang van die ontwikkeling van miokardiale hipertrofie in ‘n 
rotmodel van dieet-geïnduseerde vetsug te ondersoek en (2) om die effek van inhibisie van 
GSK-3 op die ontwikkeling van hipertrofie te ondersoek. 
Metodes: Ouderdomsgepaarde manlike Wistarrotte is in hierdie studie gebruik. Die diere is 
vir ‘n periode van 20 weke aan verskillende diëte onderwerp, naamlik standaard kommersiële 
rotkos vir die kontrole diere en ‘n hoë kalorie dieet vir die eksperimenteel vet diere (DIO).  
Helfte van elke groep diere is vir 8 weke met ‘n GSK-3 inhibitor behandel (CHIR118637, 
30mg/kg/day, Novartis). Na die 20 weke is 3 eksperimentele reekse uitgevoer: (i) Die diere is 
eggokardiografies ondersoek om in vivo miokardiale funksie te bepaal en biometriese, 
metaboliese en biochemiese parameters is evalueer.  
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(ii) Die vermoë van kardiomiosiete om de-oksiglukose na insulien stimulasie te akkumuleer, 
is bepaal, en (iii) die lokalisering van sleutelproteïene is met behulp van fluoressensie 
mikroskopie en die selgrootte met behulp van ligmikroskopie bepaal. 
Resultate en bespreking: Die hoë kalorie dieet het gepaard gegaan met ‘n beduidende 
toename in liggaamsgewig (p<0.005) en intraperitoneale vetmassa (p<0.01) in vergelyking 
met diere op die kontrole dieet. Newe-effekte geassosieerd met vetsug nl. onderdrukte 
glucose toleransie (p<0.05), hiperinsulinemie (p<0.0005) en ‘n verhoogde HOMA-IR index 
(p<0.01) is ook waargeneem. Daar was ook ‘n beduidend ingekorte respons van glukose 
opname deur kardiomiosiete van die vet diere na stimulasie met 10nM (p<0.05) en 100nM 
(p<0.05) insulien. Disregulering van PKB/Akt is gevind in die vorm van ‘n afregulering van 
die fosforilering van die proteïen (p<0.01). Die dieet het ook gelei tot die ontwikkeling van 
miokardiale hipertrofie aangesien die ventrikulêre gewig (p<0.05) asook die verhouding van 
die ventrikulêre gewig teenoor tibia lengte beduidend toegeneem het (p<0.01). 
Eggokardiografie het ‘n toename in ventrikulêre end-diastoliese dimensie in die DIO diere 
aangetoon (p<0.05). Tesame hiermee het die breedte van kardiomiosiete van die DIO diere 
toegeneem (p<0.0001) en daar was ook ‘n peri-nukluêre lokalisering van NFATc3. 
Behandeling van kontrole diere met ‘n GSK-3 inhibitor het insulienweerstandigheid ontlok 
soos afgelei uit ‘n verhoging in liggaamsgewig (p<0.05), serum insulien-vlakke (p<0.01) en 
die HOMA-IR waarde (p<0.01). In teenstelling het behandeling van die DIO diere met die 
GSK-3 inhibitor tot ‘n verbetering van insulienweerstandigheid gelei aangesien ‘n verlaging 
in serum insulien konsentrasies gevind is (p<0.05). Kardiomiosiete vanaf die behandelde DIO 
diere het ook ‘n verhoogde insulien-gestimuleerde glukose opname met 100nM insulien 
getoon (p<0.05).   
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Behandeling met die GSK-3 inhibitor het die ontwikkeling van miokardiale hipertrofie in die 
kontrole diere teweeggebring, soos aangetoon deur ‘n toename in die ventrikulêre gewig 
(p<0.05) en ‘n groter selwydte in kardiomiosiete terwyl dit geen invloed op die bestaande 
hipertrofie van die vet diere gehad het nie.  
Gevolgtrekking: Die huidige studie het getoon dat die betrokke dieet asook behandeling met 
‘n GSK-3 inhibitor insulienweerstandigheid sowel as die ontwikkelling van miokardiale 
hipertrofie in rotte ontlok. In die DIO diere het die behandeling met die GSK-3 inhibitor 
bloedglukose en insulien-vlakke verlaag en het nie hipertrofie vererger nie.  
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PROBLEM STATEMENT 
The worldwide escalation in the incidence of obesity and its strong association with insulin 
resistance, type 2 diabetes and the cardiovascular complications that accompany these disease 
states have elicited interest in the underlying mechanisms of these pathologies (Gregor MF 
and Hotamisligil GS, 2011; Galassi A et al., 2006). Aberrant protein kinase signalling has 
been implicated in obesity associated insulin resistance, diabetes and the resulting 
cardiovascular phenotype seen in obese patients (Eldar-Finkelman H et al., 2010). In insulin 
resistance, insulin is unable to fully activate protein kinase B also known as Akt (PKB/Akt). 
One of the downstream targets of this protein is glycogen synthase kinase-3 (GSK-3). 
Detrimental effects of unopposed activity of GSK-3, also in the heart, have recently been 
described (Henriksen EJ and Dokken BB, 2006). This may stand central to some of the 
adverse consequences of insulin resistance in the heart. The role of GSK-3 in the 
development of the cardiovascular complications of obesity and insulin resistance, is 
currently unknown.  
MOTIVATION FOR RESEARCH 
In our quest to understand the causes and aetiology of the development of cardiovascular 
pathology in obesity, we have focused on the insulin signalling pathway. Our laboratory uses 
a pre-diabetic model of diet induced obesity and insulin resistance. Preliminary data 
generated in our laboratory showed that there are abnormalities in the insulin signalling 
pathway (Huisamen et al., 2011). One of the abnormalities observed in this pathway, is that 
cardiomyocytes from these pre-diabetic hearts are insensitive to insulin stimulation. 
Specifically, we found a down-regulation of PKB/Akt, which is known to mediate the 
metabolic effects of insulin such as glycogen synthesis and glucose uptake (Huisamen et al., 
2011).  
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This data corroborates the findings of Henriksen EJ and Dokken BB (2006). Additionally, it 
was found that this down-regulation of PKB/Akt is associated with GSK-3 protein up-
regulation in skeletal muscle of both obese rodents and type 2 diabetic humans (Henriksen EJ 
and Dokken BB, 2006). This up-regulation of GSK-3 is thus linked with a decrease in whole 
body insulin sensitivity and attenuated glucose uptake by peripheral tissue (Michael A et al., 
2004). These abnormalities have lead to the hypothesis that since increased GSK-3 activity 
may also in turn, via serine phosphorylation of IRS-1, result in impaired insulin signalling, 
inhibition of GSK-3 should mirror the actions of insulin, thereby reducing the production of 
glucose by enhancing glucose storage to combat the hyperglycemia seen in the insulin 
resistant state and type 2 diabetes (Sutherland C, 2011).  
GSK-3 is a serine/threonine protein kinase that was discovered in the early 1980s as an 
enzyme involved in regulation of glucose metabolism (Park KW et al., 2003). Since its 
discovery, its function has been extended to a multitude of cellular processes. GSK-3 is 
described as a unique protein kinase, because, unlike most protein kinases, it is active in 
resting cells and becomes deactivated when cells are stimulated by hormones such as insulin, 
endothelial growth factor and platelet growth factor (Lee J and Kim MS, 2007; Woodgett JR, 
1994; Ciaraldi TP et al., 2007). It regulates glucose metabolism in the insulin signalling 
pathway as follows (Lee J and Kim MS, 2007): Upon insulin stimulation the linear signalling 
cascade is activated starting with the insulin receptor (IR), insulin receptor substrates (IRSs), 
phosphoinositide-3 kinase (PI3K) and PKB/Akt, leading to the phosphorylation of GSK-3α/β 
at specific Serine-21/9 residues, thereby inactivating GSK-3’s kinetic activity (Woodgett JR, 
2001). This inactivation leads to a decrease in phosphorylation of glycogen synthase (GS), 
resulting in its activation, which promotes glycogen synthesis (Eldar-Finkelman H, 2002). 
GSK-3 regulates protein synthesis in a similar fashion, where phosphorylation of GSK-3α/β 
by PKB/Akt at specific Serine-21/9 residues also leads to its inactivation.  
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This subsequently leads to the activation of the translation initiation factor 2B (eIF2B), 
resulting in an increase in protein synthesis (Welsh GI and Proud CG, 1993; Welsh GI et al., 
1997). Chronic inhibition of GSK-3 thus poses a serious problem because it may result in an 
increase in protein synthesis, hence resulting in the development of myocardial hypertrophy. 
This hypothesis is further supported by the fact that inactive GSK-3 also influences the 
activity of transcription factors, such as nuclear factor of activated T cell-c3 (NFATc3) and 
GATA-4. Active GSK-3 represses the actions of NFATc3 and GATA-4; thus inactivation 
relieves this repression and as a result these transcription factors enter the nucleus where they 
initiate the transcription of genes implicated in the development of myocardial hypertrophy 
(Graef IA et al., 1999; Morisco C et al., 2001).  
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CHAPTER 1: LITERATURE REVIEW 
 
 
1.1 The epidemiology of obesity 
Obesity is a fast growing problem that is reaching epidemic proportions worldwide (James 
PT et al., 2004). Obesity related death is the second largest environmental cause of death, 
accounting for more than 300 000 deaths per year in the United States (Mokdad AH et al., 
2001). Obesity in countries such as Brazil, China and Sub-Saharan Africa, including South 
Africa, is also increasing rapidly and exceeds levels reported in affluent countries (Kelly T et 
al., 2008). According to the World Health Organization, more than 1 billion adults worldwide 
are overweight, 300 million of whom are obese (World Health Organization, 2011). The 
World Health Organization has further projected that by 2015 there will be about 2.3 billion 
overweight adults, 700 million of whom will be obese. The National Health and Nutrition 
Examination Survey (NHANES) also reported that the prevalence of obesity in children and 
adolescents has tripled between 1980 and 2002 (Ogden CL et al., 2006). In 2002, the obesity 
epidemic in South Africa was as high as 29% in men and 56% in women (Puoane T et al., 
2002). This increasing prevalence is projected to decrease the life expectancy of current and 
future generations because obesity is associated with various co-morbidities such as insulin 
resistance, type 2 diabetes mellitus, dyslipidaemia, hypertension, stroke and coronary artery 
disease (Olshansky SJ et al., 2005; Björntorp P et al., 1988). More importantly, obesity has 
long been recognised as an independent risk factor for cardiovascular disease (CVD) (Hubert 
HB et al., 1983).  
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Major scientific advances in our understanding of the molecular pathways leading to insulin 
resistance and type 2 diabetes have been made during the last 10–15 years. However, these 
disease states still pose significant limitations when it comes to treatment. Understanding the 
pathophysiology in obesity induced insulin resistance and type 2 diabetes mellitus might 
advance this quest for novel treatment options. 
1.2 Definition of obesity 
Obesity is defined as a medical condition in which excess body fat has accumulated to the 
extent that it may have an adverse effect on health (Lopaschuck GD, 2007). Rapidly changing 
life conditions, including the easy availability of energy-dense diets (increased fat and sugar 
intake), coupled with reduced physical activity, resulting mostly from the transfer to a 
Western lifestyle, are considered to be the most important factors in the development of 
obesity (Grundy MS, 2004; Hicks R, 2006). Genetic factors play a decisive role in a minority 
of cases, and in most cases only because of an inborn predisposition (Parizkova J et al., 2007). 
The degree of obesity is most often evaluated using the body mass index (BMI). BMI is 
defined as weight in kilograms divided by height in meters squared (kg/m2); this 
measurement correlates strongly with total body fat content in adults. Accordingly, a BMI 
value of 25 is the cut-off value most used to characterize normal weight. Values of 25–30 
characterize an overweight individual, while 30–35 characterizes the 1st degree, 35–40 the 
2nd degree, and 40–45 the 3rd degree of obesity (National Institute of Health (NIH) 1998; 
WHO 2000). Unfortunately, BMI fails to consider body fat distribution. There is a growing 
body of evidence which shows that visceral fat (often referred to as abdominal or central 
obesity), is more predictive of the metabolic and cardiovascular changes that occur in obesity.  
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Thus BMI in addition to waist circumference or waist-to-hip ratio measurements are currently 
being used to accurately determine the degree of obesity in humans (Dobbelsteyn CJ, 2001).  
In animals two types of models are currently used in obesity research: genetic and dietary 
models. The former allows researchers to study the underlying biology of obesity focusing on 
specific genes and pathways, while the latter is thought to represent the etiology of obesity in 
modern society (Tschöp M et al., 2001). This high caloric diet-induced obesity model mimics 
human obesity in many aspects such as increased body weight and adiposity, increased 
circulating leptin and insulin levels, increased triglyceride levels and decreased insulin 
sensitivity (Li S et al., 2008).  
1.3 Obesity and insulin resistance 
As discussed in the previous section (1.2), obesity is regarded as a complex disease, 
ultimately caused by an imbalance between caloric intake and energy expenditure. It is 
commonly associated with alterations in metabolic function, where the development of the 
insulin resistant state is seen as the starting point of this derangement (Bogardus C et al., 
1985). Further, obesity and insulin resistance has a major pathogenic role in the development 
of type 2 diabetes mellitus (Reaven GM, 1988; Morisco C, 2006). Insulin resistance is a 
pathological state in which target cells, namely the liver, skeletal muscle, adipose tissue and 
the heart, fail to respond to normal concentrations of insulin (Mlinar B et al., 2007; Saltiel 
AR, 2001). Thus higher than normal concentrations of insulin are needed to maintain 
normoglycemia. Dysfunctional adipose tissue accounts for the major metabolic derangements 
seen in obese and insulin resistant individuals. Under normal conditions, adipose tissue acts 
as a store of surplus energy during increased food intake or reduced energy expenditure 
(Sethi JK and Vidal-Puig AJ, 2007).  
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In obesity associated insulin resistance, a prolonged caloric/energy imbalance results in 
increased lipolysis, where excessive storage of triglycerides, eventually leads to the release of 
large amounts of free fatty acids (FFA) (Hutley L and Prins JB, 2005). Additionally, 
adipocyte-derived peptides such as leptin, resistin, tumor necrosis factor-α (TNF-α), 
adiponectin, plasminogen activating inhibitor-1 (PAI-1), and interleukin-6 (IL-6) are also 
released (Vázquez-Vela ME, 2008). The excessive release of these FFA along with the 
adipocyte–derived peptides then incites lipotoxicity (Hutley L and Prins JB, 2005). The 
resulting lipotoxicity affects adipose as well as non-adipose tissue, resulting in excess fat 
being deposited in ectopic tissue such as liver, skeletal muscle, pancreas (figure 1) and the 
heart. 
In the liver, FFA causes an increased production of glucose, triglycerides and secretion of 
very low-density lipoproteins (VLDL). The associated lipid/lipoprotein abnormalities include 
reductions in high-density lipoprotein (HDL) cholesterol and an increased density of low-
density lipoproteins (LDL) (Eckel RH et al. 2005). The abnormalities associated with 
increased triglycerides include inhibition of lipogenesis, which prevents adequate clearance 
of serum triacylglycerol levels that contribute to hypertriglyceridemia. Additionally, 
increases in triglycerides cause lipotoxicity that results in insulin-receptor dysfunction. The 
consequent insulin-resistant state, arising from the receptor dysfunction, creates 
hyperglycemia with compensated hepatic gluconeogenesis. The latter increases hepatic 
glucose production, further accentuating the hyperglycemia caused by insulin resistance 
(Boden G et al., 1994; Pan DA et al., 1997). 
In the muscle, FFA inhibit insulin mediated glucose uptake which results in reduced insulin 
sensitivity, contributing to the development of hyperglycemia (Eckel J and Reinauer H, 1990; 
Eckel RH et al., 2005). 
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In the pancreas, increases in circulating FFA incite lipotoxicity and results in a decreased 
secretion of pancreatic β -cell insulin, which eventually results in β -cell exhaustion (Unger 
RH, 1995).  
The pro-inflammatory cytokines also result in enhanced hepatic glucose production, the 
production of VLDL by the liver and insulin resistance in muscle (not shown in the diagram) 
(Eckel RH et al., 2005). 
In addition to the factors named above, obesity and insulin resistance also affect the peptide 
hormone leptin. This hormone is a non-glycosylated peptide hormone that is produced by 
adipocytes (Pittas AG et al., 2004). In peripheral tissue, leptin prevents fat deposition in non 
adipose tissue, hence enhancing insulin sensitivity in muscle and fat, and also prevents 
lipotoxicity in pancreatic β -cells (Zhuang et al., 2009). Leptin dysfunction is observed in 
obesity. This dysfunction is accompanied by a substantial increase in insulin secretion from 
the pancreas, resulting in a decrease in the biological effects of insulin, hence promoting the 
development of insulin resistance (not shown in the diagram) (Seufert J, 2004). 
In the heart, exposure of the vasculature and muscle cells to high levels of FFA initiates 
multiple cellular processes, including impaired insulin signalling (Belfort R et al., 2005), 
oxidative stress (Du X et al., 2006), alterations in local rennin-angiotensin system (RAS) 
(Watanabe S et al., 2005) and enhanced vascular smooth muscle cell adrenergic sensitivity 
(Stepniakowski KT et al., 1995). All of these factors contribute to cardiac, vascular and 
metabolic insulin resistance (not shown in the diagram). 
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Figure 1: A positive energy imbalance, as a result of increased caloric intake and reduced energy 
expenditure, causes accumulation of triglycerides in adipose tissue which leads to increased lipolysis. 
The latter causes an increase of FFA in the circulation and triglycerides accumulate in non-adipose 
tissue such as the liver, pancreas and muscle. This in turn results in many of the typical features 
characteristic of the insulin resistant state (Lewis GF et al., 2002).  
mined set point at which adaptive adipose tissue insulin resis-
tance limits further adipose tissue fat accumulation, with
consequent spillover of fat to nonadipose tissues (Fig. 3).
E. Abnormal fatty acid metabolism in skeletal muscle
Intramyocellular triglyceride (IMTG) accumulation has
been associated with muscle insulin resistance in humans
(95–98). IMTG is also elevated in lean, glucose-tolerant off-
spring of twoparentswith type 2 diabetesmellitus compared
with individuals without a family history of diabetes and is
associated with lower glucose disposal (14). Somewhat par-
adoxically, however, triglycerides have also been shown to
accumulate in the muscle tissue of highly physically trained
athletes (99). As pointed out in a recent review on this topic
by Kelley and Goodpaster (100), muscle triglyceride may not
have adverse metabolic consequences in muscle that has the
capacity for efficient lipid utilization.
The mechanism accounting for the relationship between
muscle triglyceride accumulation and insulin resistance is
not known. It remains an open question as towhethermuscle
triglyceride accumulation is merely amarker or plays a caus-
ative role in the insulin resistance. A key issue is whether
triglycerides accumulate in muscle tissue of insulin-resistant
individuals as a result of a primary defect in fatty acid ox-
idation, increased total FFA flux to muscle, or due to an
imbalance between FFA uptake, esterification, triglyceride
lipolysis, and fatty acid oxidation. Muscle from obese, insu-
lin-resistant individuals and type 2 diabetic patients has been
shown to have reduced capacity for uptake and oxidation of
fatty acids derived from the plasma FFA pool during fasting
and exercise (101–105). These changes could perhaps be at-
tributed to defects of fatty acid oxidation at the carnitine
palmitoyl-transferase-1 (CPT-1) and post-CPT-1 levels (106).
Furthermore, weight reduction using low-calorie diets in
patients with type 2 diabetes has been shown to reduce
plasma FFA flux during fasting but not exercise, without
significant change in plasma-derived FFA oxidation or mus-
cle mitochondrial oxidative enzymes (102, 107). Prolonged
pharmacological inhibition of muscle CPT-1 in rats has also
been associated with IMTG accumulation and development
of insulin resistance (108). These findings have been inter-
preted to suggest that impaired muscle fatty acid oxidation
is the primary defect causing the IMTG accumulation and
muscle insulin resistance in patients with obesity, IRS, and
type 2diabetes (100). Impairedmuscle FFAoxidation in these
conditions could also be the result of excessive chronic ex-
posure to FFA, because the elevation of malonyl-coenzyme
A (CoA) due to energy excess has been associated with re-
ducedmuscle fat oxidation through inhibition of CPT-1 (109,
110). It should be pointed out that the reduction of plasma-
derived FFA oxidation seen in patients with obesity and
diabetes has been shownby some to occur in associationwith
unaltered or even elevated total fat oxidation and with ele-
vatedmuscle triglyceride lipolysis (104, 105). Thus, while the
capacity for fat oxidation appears to be reduced, total fat
FIG. 3. Positive net energy balance exceeds the buffering capacity of adipose tissue, leading to glucolipotoxicity. Positive net energy balance,
resulting from increased calorie intake and reduced energy expenditure, leads to an accumulation of triglyceride in many tissues, particularly
in adipose tissue. The accumulation of triglyceride in adipose tissue leads to increased lipolysis by a mass effect. This, associated with the
development of adipocyte insulin resistance, results in net spillover of fatty acids to nonadipose tissue, which further increases extraadipocytic
triglyceride storage, leading to many of the typical features that characterize the insulin-resistant state and type 2 diabetes.
206 Endocrine Reviews, April 2002, 23(2):201–229 Lewis et al. • Fat Metabolism in IRS and Type 2 Diabetes
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1.3.1 Actions of insulin 
Insulin is a potent anabolic hormone that is secreted by the β-cells of the pancreatic islets of 
Langerhans. It exerts a broad spectrum of anabolic effects in multiple tissues and is essential 
for appropriate tissue development, growth and maintenance of whole-body glucose 
homeostasis (Wu X and Garvey WT, 2011). In the liver and skeletal muscle insulin regulates 
glucose homeostasis by augmenting glycogen formation, it reduces hepatic glucose output by 
inhibiting gluconeogenesis and glycogenolysis, and increases the rate of glucose uptake 
(Saltiel AR and Kahn R, 2001). Insulin also affects lipid metabolism as it augments the 
availability of glycerol and fatty acids for triglyceride synthesis, by increasing the uptake of 
glucose into adipose tissue and by inhibiting lipolysis (Wu X and Garvey WT, 2011). In the 
heart, insulin regulates metabolism by modulating glucose transport, glycolysis, glycogen 
synthesis, lipid metabolism and protein synthesis (Brownsey RW et al., 1997). In addition it 
enhances cardiac contractility (Abel ED, 2004). Myocardial excitation is associated with the 
trans-membrane movement of the extracellular Ca2+ into cardiomyocytes through activated 
Ca2+ channels and reverse Na2+/Ca2+ exchange. This influx of Ca2+ stimulates the additional 
release of Ca2+ from the sarcoplasmic reticulum via the ryanodine receptors, which results in 
myofilament activation and contraction. Studies in isolated human cardiomyocytes suggest 
that insulin enhances Ca2+ influx through activation of L-type Ca2+ channels and reverse-
mode Na2+/Ca2+ exchange, thereby enhancing contraction (Maier S et al., 1999; von Lewinski 
D et al., 2005). In the vasculature, insulin stimulates an increased production of nitric oxide 
(NO) from vascular endothelium, thereby enabling vasodilation (Zeng G and Quon MJ, 1996). 
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1.3.2 Molecular mechanisms of insulin signalling 
1.3.2.1 Normal insulin signalling 
Insulin action begins with the binding of insulin to a heterotrimeric receptor on the cell 
membrane of the target cells (liver, skeletal muscle, adipose tissue and the heart). Insulin 
receptors are membrane glycoproteins composed of two α- and two β-subunits (Kido Y et al., 
2001). Binding of insulin to the extracellular α -subunit results in a conformational change 
that bring the α-subunits closer together, and enables adenosine triphosphate (ATP) to bind to 
the intracellular domain of the β-subunit, leading to autophosphorylation of distinct tyrosine 
residues on the β-subunit (Jacobs S and Cuatrecasas P, 1981; Shoelson SE et al., 1991; van 
Obberghen E et al., 2001). Ligand-dependent stimulation of the β -subunit tyrosine kinase 
activity is critical for promulgation of the insulin signal (Wu X and Garvey WT, 2011). Six 
tyrosine (Tyr) residues in the β -subunit undergo phosphorylation and have been shown to 
serve different roles in insulin signalling (Shoelson SE et al., 1991). Phosphorylation of 
Tyr972 has been shown to establish the recognition motif and docking sites, providing stability 
for substrate phosphorylation. Tyrosine phosphorylation sites at positions Tyr1158, Tyr1162 and 
Tyr1163 are essential for mediating an increase in subunit tyrosine kinase activity, while 
phosphorylation sites Tyr1328 and Tyr1334 are involved in the mitogenic responses (Cheatham 
B and Kahn CR, 1995). Following insulin binding and receptor autophosphorylation, the 
insulin receptor phosphorylates intracellular protein substrates (figure 2). Eleven intracellular 
substrates have been identified, which are rapidly phosphorylated on the tyrosine residues by 
ligand-bound insulin receptor (Saltiel AR and Kahn R, 2001). The insulin receptor substrates 
(IRSs), immediate substrates for the insulin receptor tyrosine kinases, play an important role 
in the actions of insulin. IRSs propagate insulin signal transduction through docking, 
apposition, interaction and activation of downstream signalling molecules. This provides a 
point of divergence of the insulin transduction pathway (Khan AH and Pessin JE, 2002).  
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This divergence leads to the activation of the metabolic phosphoinositide-3 kinase (PI3K), 
Cbl-associated protein (CAP)/ Casitas b-lineage lymphoma (CbI)/ TC10 and mitogenic 
(rennin-angiotensin system (RAS)/Mitogen activated protein (MAP) kinase) pathway (Saltiel 
AR and Kahn R, 2001; Khan AH and Pessin JE, 2002). Binding of IRS1-4 to PI3K is critical 
in mediating the metabolic effects of insulin (Gual P et al., 2005; White MF, 2002). Upon 
phosphorylation of the p85 subunit of PI3K it associates with the p110 subunit to produce 
phosphatidylinositol-3,4,5-phosphate PI(3,4,5)P3 through phosphorylation on the 3 position 
of the integral membrane protein, phosphatidyl inositol 4,5 bisphosphate (PIP2). This leads to 
the recruitment and activation of phosphoinositide-dependent protein kinase 1 (PDK1) which 
is responsible for the downstream activation of atypical protein kinase C (PKC) ζ on 
Threonine 410 (Thr410) and PKB/Akt on Thr308, thereby enhancing the activity of these 
kinases (Wu X and Garvey WT, 2011).  
PKB/Akt is a serine/threonine protein kinase with a molecular weight of 57 kDa (Hajduch E 
et al., 2001). This kinase is a critical signalling molecule in all eukaryotic cells and has 
diverse functions in human physiology and diseases (Manning BD and Cantley LC, 2007). 
There are three PKB/Akt isoforms, i.e. PKB/Akt1, PKB/Akt2 and PKB/Akt3 (α, β and γ) 
present in higher eukaryotes, and each has an amino terminal pleckstrin homology (PH) 
domain, a kinase domain and a carboxyl terminal regulatory domain (Hajduch E et al., 2001). 
PKB/Akt is well established as an effector of the PI3K signalling pathway in all cells 
(Fruman DA and Cantley LC, 2002), and is regulated by phosphorylation. In the PI3K 
pathway PIP2 and PIP3 bind to the PH domain of PKB/Akt, therefore altering its 
conformation, leading to its phosphorylation and activation (Hajduch E et al., 2001). This 
phosphorylation takes place at Thr308 of the kinase domain and Serine 473 (Ser473) of the C-
terminal domain (Coffer PJ et al., 1998).  
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Upon activation, PKB/Akt phosphorylates and controls the activities of several downstream 
substrates. In glucose metabolism PKB/Akt is involved in translocation of glucose 
transporters (mainly GLUT 4) to the plasma membrane, thereby promoting glucose uptake by 
the cells (Khan AH and Pessin JE, 2002). Once plasma glucose is available in excess, 
PKB/Akt phosphorylates GSK-3, which normally phosphorylates and inhibits glycogen 
synthase (GS), a rate-limiting enzyme of glycogenesis. Inhibition of GSK-3 by PKB/Akt thus 
favours glycogen synthesis and storage in muscles, liver, adipose tissues and the heart 
(Hajduch E et al., 2001). 
 
In parallel with the PI3K pathway the CAP/Cbl/TC10 pathway also participates in glucose 
uptake stimulation (Watson RT and Pessin JE, 2001). This pathway diverges at the level of 
the insulin receptor kinase, which mediates tyrosine phosphorylation of the Cbl proto-
oncogene through a process that does not involve IRSs. In this pathway, prior to the 
phosphorylation step of Cbl, the adaptor protein (APS) is recruited to the insulin receptor β-
subunit. This results in Cbl binding to APS, permitting the phosphorylation of Cbl. The Cbl 
associated protein (CAP) is also recruited with Cbl, resulting in a cascade which reinforces 
glucose uptake stimulation, by inducing GLUT-4 translocation, which is also stimulated by 
the PI3K pathway (Baumann CA et al., 2002).  
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Another component of signal divergence comes from engagement of the RAS/MAP kinase 
signalling pathway (figure 2), which is critical in cell growth and mitogenesis. In this 
pathway the insulin receptor mediates the activation of the RAS/MAP kinase pathway 
through the activation of substrate docking molecules such as SHC, Growth factor receptor-
bound protein 2 (Grb2) (a small cytosolic adaptor protein), murine Son of Sevenless (mSOS) 
(GDP/GTP exchange factor) and Ras. Ras activation triggers the activation of Rapidly 
accelerated fibrosarcoma (Raf-1) kinase. Raf-1 kinase then initiates a cascade leading to 
sequential phosphorylation and activation of kinase MEK (MAPK/ERK kinase), which in 
turn phosphorylates extracellular regulated kinases (ERK1 and ERK2) on their threonine and 
tyrosine residues. These activated ERKs phosphorylate multiple targets that mediate the 
mitogenic actions of the Ras/MAP kinase pathway and the growth promoting effects of 
insulin (Boulton TG et al., 1991). Changes in this pathway were not addressed in this study. 
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Figure 2: Principal components of the insulin signalling pathway showing the metabolic and 
mitogenic effects of insulin. The arrows represent an activation process, blocked arrows 
represent an inhibition process. Adapted from Wu X and Garvey WT (2011). 
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1.3.2.2 Impairment of insulin signalling resulting in insulin resistance 
Defects in the actions of insulin occur at several levels in the insulin signalling pathway. At 
the insulin receptor level, the number of cell-surface receptors, in target tissue such as the 
liver, skeletal muscle and the heart, are down-regulated by chronic exposure to high 
concentrations of insulin, in vivo (Muniyappa et al., 2007). This affects insulin-stimulated 
glucose uptake and activation of glycogen synthase (GS) (Brunning JC et al., 1998; Okamoto 
H et al., 2004). In a knockout mouse model with a decrease in cell-surface insulin receptors 
in skeletal muscle, the animals were shown to have features of the metabolic syndrome, 
including an increase in fat mass, triglycerides and serum FFA, but retained normal basal 
glucose transport (Wojtaszwewski JF et al., 1999). This phenotype was analogous to that 
seen in patients with insulin resistance, where defects in the insulin receptors also resulted in 
the development of severe insulin resistance and glucose intolerance. In endothelial cells, a 
decrease in the IRs causes a decrease in the production of NO, which affects vasodilation 
(Muniyappa R et al., 2007). This shows that the functional activity of the insulin receptors is 
critical for effective insulin action. Regarding the insulin receptor substrate, it was found that 
deletion of IRS1 produced insulin resistance in mice (Deborah J et al., 2001). In another 
experiment, it was shown that mice lacking IRS2 develop severe diabetes at 8-15 weeks of 
age; this was attributed to the reduction in β-cell mass and reduced secretion of insulin, hence 
insulin no longer served a compensatory role (Hirashima Y et al., 2003). IRSs propagate the 
insulin signal transduction and activate downstream signalling molecules. Theoretically, 
defects at receptor level influences many downstream signalling molecules in the insulin 
signalling pathway, resulting in the pathogenesis of many diseases.  
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1.4 General aspects of myocardial hypertrophy 
Wang X and colleagues (2003) defined cardiac hypertrophy as an adaptive response of the 
heart to hemodynamic overload during which terminally differentiated cardiomyocytes 
increase in size without undergoing cell division. This hypertrophic response can broadly be 
classified as either physiological or pathological cardiac hypertrophy (figure 3) (Nadal-
Ginard B et al., 2003; Bernardo BC, 2010). The former occurs during growth, or it can be 
induced by endurance exercise and it can also be observed during pregnancy. Pathological 
cardiac hypertrophy, on the other hand, is a response to stress signals that arise from a variety 
of cardiovascular disorders, including pressure and volume overload due to valvular 
dysfunction, arterial hypertension, ischemic heart disease or intrinsic contractile 
abnormalities resulting from sarcomere protein mutations. Pathological and physiological 
hypertrophy can also be sub classified as concentric or eccentric hypertrophy (figure 4) 
(Grossman W et al., 1975; Pluim BM et al., 2000; Agrawal R et al., 2010; Bernardo BC, 
2010), where the former results in an increase in the number of parallel contractile elements 
which leads to an increase in wall thickness which lowers wall stress. This phenomenon 
generally occurs as a result of pressure overload, for example in hypertensive patients. 
Eccentric hypertrophy, on the other hand, results in an increase in chamber size and end-
diastolic volume and enhances stroke volume. This phenomenon is observed when the heart 
is subjected to volume overload, for example owing to valve defects. The concomitant 
change in chamber cavity size and geometry induce detrimental effects in the long-term when 
cardiac output fails to meet the increased demand (Jacob R and Gulch RW, 1998). The 
defining features of hypertrophy are an increase in cardiomyocyte size, enhanced protein 
synthesis, an overt increased risk of ventricular dysfunction and a higher organisation of the 
sarcomere.  
Stellenbosch University http://scholar.sun.ac.za
15	  
 
Figure 3: Cardiac hypertrophy can be classified as physiological or pathological. The 
former is reversible and is characterized by normal cardiac morphology and function. In 
contrast, hypertrophy that occurs in settings of disease (pathological hypertrophy) is 
detrimental for cardiac structure and function and can lead to heart failure (Bernardo et al., 
2010).  
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Figure 4: Different stimuli induce different forms of cardiac hypertrophy. Pressure overload 
causes thickening of the left ventricle wall due to the addition of sarcomeres in parallel and 
results in concentric hypertrophy. Volume overload induces an increase in muscle mass via 
the addition of sarcomeres in series and results in eccentric hypertrophy (Bernardo et al., 
2010). 
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1.4.1 Overview of the signalling cascade/proteins implicated in mediating physiological and 
pathological hypertrophy 
Physiological hypertrophy is mediated by growth factors such as insulin like growth factors 
(IGF) and growth hormone (Reviewed by Bernardo et al., 2010). These growth factors 
interact with their tyrosine kinase associated receptors, which cause receptor dimerisation, 
autophosphorylation and activation of PI3K. As described previously, this kinase transforms 
PIP2 into PIP3, which recruits a second kinase PKB/Akt to the plasma membrane and causes 
its phosphorylation. This phosphorylated PKB/Akt can by itself induce the expression of 
hypertrophy-associated genes. Downstream of PKB/Akt, inhibition of GSK-3 can further 
promote this hypertrophic response by promoting protein synthesis or by activating the 
transcription of genes which mediate the hypertrophic response. Pathological hypertrophy, on 
the other hand, is caused by activation of the neurohormonal pathway that involves 
angiotensin II, endothelin I or catecholamines. They all produce pathological hypertrophy 
through the activation of the Gαq coupled signalling pathway, which subsequently activates 
phospholipase Cβ. This phospholipase hydrolyses PIP2 to Diacylglycerol (DAG) and Inositol 
trisphosphate (IP3). IP3 results in the release of Ca2+ from intracellular stores and also 
activates the phosphatase calcineurin. Calcineurin regulates the alterations in gene expression 
that are associated with pathological hypertrophy by dephosphorylating the transcription 
factor nuclear factor of T cell (NFAT) (Molkentin JD et al., 1998). This dephosphorylation of 
NFAT causes its nuclear translocation and modulates gene expression. By contrast, DAG 
activates members of the PKC family, which can also contribute to the altered regulation of 
gene expression observed in cardiac hypertrophy (figure 5). 
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Figure 5: A schematic overview of the signalling pathways of pathological and physiological 
hypertrophy. Outlined are the key initiating stimuli, signalling pathways, cellular responses 
and cardiac function consequences of each pathway (Bernardo et al., 2010).  
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1.5 Obesity and the development of myocardial hypertrophy 
Heart failure is defined as “a complex clinical syndrome that can result from a structural or 
functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood. 
The cardinal manifestations of heart failure are dyspnea and fatigue, which may limit exercise 
tolerance; and fluid retention, which may lead to pulmonary congestion and peripheral edema” 
(ACC/AHA, 2005). This syndrome is divided into 4 stages, A, B, C and D, as defined by 
American College of Cardiology/American Heart Association (ACC/AHA, 2005). In stage A, 
patients show no symptoms of heart failure, no structural alteration, but are at risk of 
developing heart failure because of comorbidities such as coronary artery disease, 
hypertension or diabetes mellitus. In stage B, patients still do not show symptoms of heart 
failure, but have developed structural abnormalities, such as left ventricular hypertrophy, 
ventricular dilation, valvular disease or previous myocardial infarction. In stage C, patients 
have symptomatic heart failure and are in therapy. Finally, in stage D, patients have end-stage 
heart failure and are receiving maximal medical therapy (ACC/AHA, 2005; Klein L et al., 
2003). Heart failure arises from a variety of aetiologies, including obesity. This association 
between obesity and heart failure has been under-recognized in the past, however, an 
increasing number of epidemiologic studies now report this association (Duflou J et al., 1995; 
Dwyer EM et al., 2000). Clinical studies have also confirmed the association of adiposity 
with left ventricular dysfunction, independent of hypertension, coronary artery disease and 
other heart disease (Hubert HB et al., 1983; Kenchaiah S et al., 2002). Most types of heart 
failure are preceded by cardiac hypertrophy. In obesity the increase in extracellular volume, 
which consists of the intravascular space and interstitial fluid space, is identified as one of the 
ways in which obesity can result in the development of myocardial hypertrophy.  
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This expansion of total blood volume leads to increased left ventricular filling, which in turn 
leads to chamber dilation and increased cardiac output (Licata G et al., 1991; Alexander JK; 
1985). The majority of the literature suggests that an increase in stroke volume accounts for 
the increase in cardiac output in obese individuals (Messerli FH et al., 1982). To compensate 
for these factors, adaptive myocardial hypertrophy together with left ventricular dilation 
occurs, resulting in eccentric hypertrophy. Adaptive myocardial hypertrophy is initially a 
compensatory mechanism, aimed at maintaining cardiac output. However, with time, this left 
ventricular dilation increases wall stress, which stimulates left ventricular myocardial growth 
and leads to an elevation in left ventricular mass, indicating a decompensated myocardial 
hypertrophic state (Opie LH, 1991). It is within this setting that the development of heart 
failure arises.  
In addition to structural changes, obesity also results in changes in cardiac function. Many 
studies have evaluated left ventricular (LV) systolic function in obesity. The findings from 
these studies vary, where some groups report normal or improved ejection fraction (EF) and 
fractional shortening (FS), implying that these individuals have improved systolic function. 
Other studies have, however, reported depressed ejection fraction (EF) and fractional 
shortening (FS) values (Abel ED et al., 2008). This difference in findings could be due to the 
prevalence of comorbidities, such as hypertension, diabetes and vascular diseases, which can 
independently contribute to the development of LV dysfunction. Also, the difference in 
techniques used by the different groups can account for the heterogeneity in the findings. The 
use of more sensitive equipment, such as Tissue Doppler Imaging, which in addition to EF 
and FS, measures sensitive parameters, such as end-systolic and -diastolic diameter, end-
systolic and -diastolic volumes, relative wall thickness, mean velocity circumferential 
shortening, pre-ejection period and ejection period, gives a clearer picture of the effects of 
obesity on LV systolic function.  
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Studies using these sensitive methods have revealed that, despite normal EF values in obese 
individuals, myocardial function remains reduced. Furthermore, they also observed a 
reduction in myocardial contractility (Garavaglia GE et al., 1988). The studies that have 
evaluated LV diastolic function in obesity have also given variable results. Using Tissue 
Doppler Imaging, two groups have reported evidence of reduced early diastolic tissue 
velocity and diastolic strain rate in obese individuals compared to normal weight subjects 
(Wong CY et al., 2004). Decreases in these parameters are associated with a decrease in the 
rate of LV relaxation (Pascual M et al., 2003). 
1.6 General overview of the GSK-3 protein 
Glycogen synthase kinase-3 (GSK-3) was identified in the early 1980s as an enzyme 
involved in the control of glycogen metabolism (Woodgett JR and Cohen P, 1984). In recent 
years GSK-3 has been reported to participate in a multitude of cellular processes, ranging 
from cell membrane-to-nucleus signalling, gene transcription, protein translation and 
cytoskeletal organisation to cell cycle progression and survival, to name a few (Meijer L et 
al., 2004). GSK-3 is a serine/threonine kinase that is ubiquitously expressed (Park KW et al., 
2003). In humans there are two GSK-3 isoforms, GSK-3α with a molecular weight of ~51 
kDa and GSK-3β with a molecular weight of ~47 kDa, that account for all GSK-3 activity 
(Woodgett JR, 1990). In addition, the GSK-3β mRNA undergoes alternative splicing between 
exon 8 and 9 that produces two different protein products, namely GKS-3β1 and GSK-3β2 
(Mukai F et al., 2010; Sutherland C, 2011). The protein isoforms of GSK-3 are encoded by 
two distinct genes located on chromosomes 19q13.1-2 and 3q13.3-q21 (Woodgett JR, 1990). 
These isoforms exhibit a high degree of sequence similarity in their catalytic domains, 
however, outside of this kinetic domain, their sequence differ substantially and little is known 
about their isoform-specific functions (Ciaraldi TP et al., 2007).  
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Therefore, despite the fact that these isoforms are structurally similar, their expression 
patterns, substrate preferences and cellular functions are not identical (Woodgett JR, 2001). 
Genetic ablation of one or both of the GSK-3 isoforms has provided clues as to cellular 
processes governed by their activity. In genetic knockout studies performed by Hoeflich KP 
and colleagues (2000) it was found that mice embryos carrying homozygous deletions of 
exon 2 of the GSK-3β isoform suffer from massive liver degeneration caused by extensive 
hepatocyte apoptosis, leading to death at around embryonic day 16. This lead to the 
conclusion that GSK-3β function is not compensated for by GSK-3α. In another study, 
MacAulay K and colleagues (2005) found that mice lacking GSK-3α remained viable and 
exhibited a small improvement in insulin sensitivity and glucose tolerance. 
1.6.1 Regulation of the GSK-3 protein 
As stated previously, GSK-3 is involved in many cellular processes, thus regulation of its 
activity is critical to ensure that signalling pathways are appropriately coordinated. To 
achieve this, GSK-3 is subject to many levels of regulation. These include regulation by 
phosphorylation, cellular localisation and protein-protein interactions.  
1.6.1.1 Regulation by phosphorylation 
GSK-3 is described as a unique protein kinase, because unlike most protein kinases, it is 
active in resting cells and becomes deactivated when cells are stimulated by hormones such 
as insulin, endothelial growth factor and platelet growth factor (Woodgett JR, 1994; Ciaraldi 
TP et al., 2007). The most well defined mechanism of GSK-3 regulation is the 
phosphorylation of the N terminal at Serine 9 (Ser9) in GSK-3β and Serine 21 (Ser21) in the 
GSK-3α isoform (Markou T et al., 2008).  
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The following substrate proteins can phosphorylate GSK-3 on serine residues, thus having an 
inhibitory effect on its activity: PKB/Akt (PI3K pathway), some isoforms of PKC, protein 
kinase A (PKA), p90RSK and p70S6 kinase (Murphy E and Steenbergen C, 2005). GSK-3 is 
also inhibited by cardiac hypertrophic stimuli induced by the activation of endothelin-1 and 
Fas, in response to pressure overload (Haq S et al., 2000). In addition, the actions of GSK-3 
are regulated by the phosphorylation state of its substrates. This is due to the fact that most 
GSK-3 substrates, but not all, must be pre-phosphorylated or primed in order for GSK-3 to 
phosphorylate them. GSK-3 has been shown to phosphorylate non-primed substrates, but this 
results in less efficient phosphorylation. In contrast to inactivation via serine phosphorylation, 
GSK-3 can be phosphorylated on tyrosine residues, resulting in its activation, i.e. Tyr279 of 
GSK-3α and Tyr216 of the GSK-3β isoform (Murphy E and Steenbergen C, 2005). This 
means that GSK-3 tyrosine phosphorylation results in facilitative autophosphorylation, while 
serine phosphorylation is regulatory. The kinase responsible for tyrosine phosphorylation of 
GSK-3 protein is poorly understood.  
1.6.1.2 Regulation by cellular localisation 
Intracellular localization of GSK-3 isoforms controls its access to its substrates. GSK-3 is 
predominantly localised in the cytosol, however, it can also be present in the nucleus and 
mitochondria. The level of GSK-3 in any compartment is not static but changes dynamically 
in response to intracellular cues. For example, during the G1 phase of the cell cycle, GSK-3β 
is located predominantly in the cytoplasm, but during the S phase, a significant fraction enters 
the nucleus, promoting its ability to phosphorylate cyclin D1 in the nucleus (Diehl JA et al., 
1998; Jope RS and Johnson GVW, 2004).  
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1.6.1.3 Regulation by protein-protein interactions 
GSK-3 activity can also be regulated by protein-protein interactions, an example being in the 
canonical Wnt signalling pathway (Jope RS and Johnson GVW, 2004). In this pathway the 
absence of a Wnt signal causes β -catenin to assemble in a cytosolic multi-protein complex 
composed of APC (tumour suppressor protein), GSK3 and the scaffolding protein axin. A 
sequential phosphorylation of β-catenin by casein kinase I and by GSK 3 at Ser/Thr residues 
targets β-catenin for ubiquitination and proteasomal degradation. In the presence of Wnt, β-
catenin phosphorylation and degradation is inhibited, resulting in β -catenin being available 
for transcriptional regulation. This pathway serves as a classic example of how GSK-3 in 
complex with other proteins regulates cellular function (figure 6). 
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Figure 6: An overview of the Wnt signalling pathway: In this pathway, signals are 
transmitted from the extracellular signalling protein Wnt to the transcriptional regulator β 
catenin, which controls the expression of numerous target genes, including the gene for 
cyclin D1 and the transcription factor Myc. β-catenin may exist in a membrane bound form in 
complex with the cell adhesion molecule E-cadherin or in a cytosolic form. In the absence of 
a Wnt signal (Figure A) β -catenin is assembled in a cytosolic multi protein complex 
composed of APC (tumour suppressor protein), GSK3 and the scaffolding protein axin. A 
sequential phosphorylation of β-catenin by casein kinase I and by GSK 3 at Ser/Thr residues 
marks β-catenin for ubiquitination and proteasomal degradation. In the presence of Wnt 
(Figure B), β -catenin phosphorylation and degradation is inhibited, and β -catenin is 
available for transcriptional regulation (Rayasam GV et al., 2009).   
1.6.2 Substrates of the GSK-3 protein 
There are a number of proteins that have been identified as GSK-3 substrates. These proteins 
are implicated in a multitude of cellular processes. Of particular importance to our study are 
the following substrate proteins: GS, implicated in the insulin signalling pathway, and; NFAT 
and GATA-4, implicated in the pathogenesis of myocardial hypertrophy.  
1.6.3 The role of GSK-3 protein in the development of insulin resistance and type 2 diabetes 
mellitus  
Whole–body blood glucose homeostasis is a continuous process that is controlled by the 
efficient absorption of glucose and storage of excess glucose as glycogen. Glycogen synthase 
(GS) is a key enzyme which mediates the conversion of glucose to glycogen. In unstimulated 
cells GS is inactive. Insulin activates GS by inactivating GSK-3 (Cross DA et al., 1995; 
Rayasam GV et al., 2009). This inactivation leads to a decrease in phosphorylation of GS, 
resulting in its activation, which promotes glycogen synthesis.  
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Abnormal GSK-3 activity has been implicated in the pathogenesis of insulin resistance and 
type 2 diabetes mellitus. Increased expression and activity of GSK-3 has been reported in the 
skeletal muscle of type 2 diabetes mellitus patients (Henriksen EJ and Dokken BB, 2006). 
This increase was associated with reduced muscle glycogen deposition. An increase in GSK-
3 activity was also found in animal models. Eldar-Finkelman H et al. (1999) found that GSK-
3 kinetic activity was higher in the fat cells of a C57/BL6 mouse strain fed a high caloric diet. 
These findings lead to the hypothesis that increased GSK-3 kinetic activity might result in 
impaired insulin signalling, which is implicated in the pathogenesis of the insulin resistant 
state and the development of type 2 diabetes. GSK-3 can also phosphorylate IRS-1 on a 
serine residue, thereby down-regulating glucose uptake (Eldar-Finkelman H and  Krebs EG, 
1997). This phosphorylation of IRS-1 by GSK-3 impairs insulin action (Eldar-Finkelman H 
and  Krebs EG, 1997). Therefore, inhibition of GSK-3 should mirror the actions of insulin, by 
reducing glucose production and enhancing glucose storage to combat the hyperglycemia 
seen in the insulin resistant state and type 2 diabetes (Sutherland C, 2011). Many 
pharmaceutical companies have thus embarked on a quest to generate potent selective 
inhibitors of GSK-3 as potential antidiabetic agents which lower blood glucose.  
1.6.4 The role of GSK-3 protein in the development of myocardial hypertrophy  
1.6.4.1 NFAT proteins and GATA-4 transcription factors 
NFAT proteins are a family of Rel homology domain containing transcription factors 
composed of five members: NFAT1 (also known as NFATp or NFATc2), NFAT2 (also 
known as NFATc or NFATc1), NFAT-3 (also known as NFATc4), NFAT4 (also known as 
NFATx or NFATc3) and NFAT5 (Hogan PG et al., 2003).  
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The regulatory domain of NFAT mediates its activation, and calcium signalling mediates the 
effects of NFAT proteins. Upon calcium stimulation, hyper-phosphorylated NFAT proteins 
are dephosphorylated by calcineurin. This dephosphorylated NFAT then translocates to the 
nucleus, where it can complex with activated MEF2, and modulate gene transcription. In 
cardiac muscle, MEF2 is likely to cooperate with NFAT in the development of cardiac 
hypertrophy (Ramirez MT et al., 1997; Molkentin JD et al., 1998; Passier R et al., 2000). 
This was demonstrated in a study where NFATc deficient mice were generated for direct 
evaluation of NFAT function. In this study they found that NFATc3 was partially responsible 
for calcineurin induced hypertrophy, as demonstrated by an attenuated hypertrophic response 
to pressure-overload in NFATc3 deficient mice (Wilkins BJ et al., 2002). Besides calcineurin, 
nuclear translocation of NFAT is influenced by a number of parallel signalling pathways in 
the regulation of the hypertrophic response. GSK-3 is a downstream effector of the PI3K-
PKB/Akt pathway and is essential for physiological hypertrophy. GSK-3 phosphorylates 
NFAT proteins, inhibiting both their nuclear localization and DNA-binding activity (Graef IA 
et al., 1999). Overexpression of constitutively active GSK-3 mutants attenuated the 
hypertrophic response in cultured cardiac myocytes and induced NFAT translocation 
(Morisco C et al., 2000; Haq S et al., 2000). Transgenic expression of the same mutant 
inhibited hypertrophic growth in response to isoproterenol stimulation and pressure overload. 
These data suggest that other signalling pathways, particularly insulin signalling as found in 
the insulin resistant state, can also influence NFAT activity, which is implicated in the 
development of myocardial hypertrophy. Besides kinase regulation, the transcriptional 
activity of NFAT is also regulated by interaction with other transcription factors such as 
GATA-4, co-activators such as Ras and co-repressors such as MEK1 (Ichida M and Finkel T, 
2001).  
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GATA proteins serve as binding partners for NFAT. GATA transcription factors are required 
for binding to the specific consensus DNA sequence (A/T)GATA(A/G) (Patient RK and 
McGhee JD, 2002). The GATA family consists of six proteins, GATA 1-6. GATA 1, 2 and 3 
are important regulators of hematopoietic stem cells and their derivatives, whereas GATA-4, 
5, and 6 are expressed in various mesoderm and endoderm-derived tissues, including the 
heart (Molkentin JD, 2000). GATA-4 plays an essential role in activating the myocardial 
hypertrophic gene program. This was demonstrated in a study where they found that 
overexpression of GATA-4 induced a greater than 2-fold increase in cardiac myocyte size in 
cultured cardiomyocytes (Pikkarainen S et al., 2004; Molkentin JD, 2000). In a mouse model 
this hypertrophy further led to contractile dysfunction at 8 months of age. These results thus 
suggest that GATA-4 is a sufficient transcriptional regulator for the development of cardiac 
hypertrophy. GATA-4 activity is regulated by several signalling molecules including Erk, 
p38 MAPK and GSK3. GSK3 negatively regulates GATA-4 transcriptional activity through 
N-terminal phosphorylation. This phosphorylation subsequently promotes nuclear export of 
GATA-4. In transgenic mouse hearts expressing an activated mutant of PKB/Akt, it was 
found that GSK3 is hyperphosphorylated and inhibited (Condorelli G et al., 2002). This 
inhibition of GSK-3 subsequently resulted in nuclear accumulation of GATA-4. This data 
shows that nuclear shuffling of GATA-4 represents an important mechanism whereby GSK3 
regulates cardiac hypertrophy. 
1.6.5 Inhibition of the GSK-3 protein 
Aberrant protein kinase signalling has been implicated in obesity associated insulin resistance, 
diabetes and the resulting cardiovascular phenotype seen in obese patients. Protein kinases 
have thus become important targets for the development of therapeutic agents. Glycogen 
synthase kinase-3 is one such kinase which has received particular attention.  
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This has led to the development of a new generation of GSK-3 inhibitors with specific 
clinical implications, especially in the potential of these inhibitors to treat diseases such as 
type 2 diabetes, muscle hypertrophy, Alzheimer’s disease, certain types of cancer, bipolar- 
and mood disorders, to name a few, that currently have significant limitations in therapeutic 
treatment. Lithium was the first GSK-3 inhibitor to be discovered and has been widely used 
to test the role of this enzyme in many disease states (Klein PS and Melton DA, 1996). 
However, it is non-specific and this has led to the development of potent, more specific 
inhibitors of GSK-3. There are three distinct regions of GSK-3 that are targeted by inhibitors 
to suppress its activity, namely the Metal ion (Mg+2) binding site, the substrate interaction 
domain and the ATP binding pocket (van Wauwe J and Haefner B, 2003). Most of the GSK-3 
inhibitors that are available are ATP competitive inhibitors. As discussed in the preceding 
literature review, dysregulation of GSK-3 may affect the state of insulin resistance as well as 
the development of myocardial hypertrophy. In addition, it was found that GSK-3 is 
overexpressed in the muscle of type 2 diabetic patients. In this study we therefore researched 
the effects of a GSK-3 inhibitor supplied by Novartis namely an aminopyrimidine class, 
CHIR118637 (CT20026), GSK-3 inhibitor developed by Chiron. This class of inhibitors are 
also ATP competitive inhibitors. They have been shown to be very specific and inhibit the 
kinetic activity of both GSK-3 α and β isoform. 
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1.7 Hypothesis	  
Chronic inhibition of GSK-3 will (i) induce myocardial hypertrophy in control animals or (ii) 
exacerbate the development of existing hypertrophy in a pre-diabetic model of diet induced 
obesity and insulin resistance. 
1.8 Objectives	  
1. Assess the extent of the development of myocardial hypertrophy in a rat model of diet 
induced obesity and insulin resistance. 
2. Assess the expression levels of GSK-3 protein in the heart of the pre-diabetic animals in 
comparison to controls. 
3. Assess the effect of inhibition of GSK-3 protein on the development of myocardial 
hypertrophy in both control and pre-diabetic animals 
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2 CHAPTER 2: MATERIALS AND METHODS 
 
 
2.1 Animals 
An experimental design was employed in this study where age-matched male Wistar rats 
were used. At four weeks after birth, the rats were weaned and placed on a standard rat chow 
diet. The animals were housed at the University of Stellenbosch Central Research Facility 
and had free access to food and water, with temperature and humidity kept constant at 22ºC 
and 40%, respectively. Furthermore, a 12 hour artificial day/night cycle was maintained. 
Throughout the study, the revised South African National Standard for the care and use of 
laboratory animals for scientific purposes was followed (SABS, SANS 10386, 2008). The 
study was assessed and approved by the Committee for Ethical Animal Research of the 
Faculty of Health Sciences, University of Stellenbosch. Ethics approval number is: 
10GK_HUI01. 
2.2 Grouping, feeding and treatment 
When the animals had reached the desired weight (180±20g), they were randomly assigned to 
two groups and were placed on separate diets for 20 weeks. Control animals (n=34) received 
the standard rat chow (SRC), consisting of 60% carbohydrates, 30% protein and 10% fat, 
while the diet animals (n=34) received the high caloric diet (HCD), which resembles a 
Western-type diet, consisting of 65% carbohydrates, 19% protein and 16% fat (Pickavance 
LC et al., 1999) (table 1). The high caloric diet was prepared to contain 33% SRC, 33% 
sweetened full cream condensed milk (Clover R), 7% sucrose and 27% water (Pickavance LC 
et al., 1999) (table 2). Animals on the high caloric diet had a higher intake of calories per day 
compared to their age-matched control counterparts; 570±23kJ and 371±18kJ (table 1). 
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Table 1: Dietary composition and energy consumption of control and diet induced obesity 
(DIO) rats (Du Toit EF et al., 2005; Pickavance LC et al., 1999).  
 Control  Diet Induced Obesity (DIO)  
Carbohydrates  60%  65%  
Protein  30%  19%  
Fat  10%  16%  
Energy consumption  371±8 kJ/day 570±23 kJ/day  
 
Table 2: Dietary composition of high caloric diet (Pickavance LC et al., 1999). 
High caloric diet composition 
Standard rat chow (SRC)  33%  
Sweetened full cream condensed milk (Clover ®)  33%  
Sucrose  7%  
Distilled water  27%  
 
Obesity in this model is induced by means of hyperphagia, and not by means of changes in 
the dietary composition of the food (Pickavance LC et al., 1999). Hyperphagia-induced 
obesity in rats has been characterized in our laboratory and shown to be physiologically 
relevant and comparable to the human equivalent of metabolic syndrome as a result of 
obesity (Du Toit EF et al., 2005). It was observed that, after 16 weeks of this diet, the animals 
developed signs of myocardial hypertrophy (Du Toit EF et al., 2008). In order to ensure that 
hypertrophy was well pronounced in our model of diet induced obesity (DIO), a feeding 
period of 20 weeks was chosen, as opposed to the 16 weeks previously employed in our 
laboratory.  
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For a period of 8 weeks, beginning in week 13, half of the animals in both groups (control 
group: n=17 and diet group: n=17) received Glycogen Synthase Kinase (GSK)-3 inhibitor 
CHIR118637 (CT20026) treatment (supplied by Novartis). Chirone (CHIR118637) inhibitors 
are ATP competitive inhibitors, have been shown to be specific and target both GSK-3α and 
β isoforms (Cline GW et al., 2002; Meijer L et al., 2004). The GSK-3 inhibitor was 
administered to the rats individually, in the form of gelatine/ jelly cubes of equal size and 
volume (1 ml), to ensure absolute compliance and dose control. The dose of GSK-3 inhibitor 
was calculated based on the normal daily dosage prescribed by the manufacturer of 30 
mg/kg/day.  
2.3 Overview of experimental procedures 
At the end of the 20 week time period, three series of experiments were conducted (figure 8). 
(i) The animals were fasted overnight and were subjected to echocardiography (n=6) (see pg. 
36) to determine in vivo myocardial function and morphology. Afterwards, the animals were 
sacrificed by intra-peritoneal injection of sodium pentobarbital at a dose of 160mg/kg 
followed by exsanguination. The animals were continually monitored until total loss of 
consciousness was observed, as indicated by a total lack of response after a foot pinch. The 
body weight of sedated animals was recorded and blood collected via a once-off tail prick for 
measurement of plasma glucose concentration using a glucometer (GlucoPlusTM, Montreal, 
Canada). The hearts were removed, weighed, snap frozen and stored in liquid nitrogen for 
subsequent biochemical analysis to determine the expression of GSK-3, PKB/Akt, NFAT-3 
and GATA-4. Further incisions were made exposing the fat masses in the viscera. The 
peritoneal and retroperitoneal fat were removed and weighed as a measurement of adiposity 
and to estimate the degree of obesity. The tibia was removed and its length determined.  
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Blood was collected from the abdominal cavity and subjected to centrifugation (micro-
centrifuged at 1000 g at 4°C for 15 min); where after the serum aliquots were stored at 
−80 °C, to be used for metabolic analysis at a later stage. The serum insulin and blood 
glucose values that were obtained were used to calculate the Homeostatic model assessment 
of insulin resistance (HOMA-IR) (Matthews DR et al., 1985). Finally the lungs were 
removed and their wet weight was recorded. (ii) The animals were sacrificed and 
cardiomyocytes were prepared. The ability of the cells to accumulate radiolabelled deoxy-
glucose after stimulation with insulin was determined. (iii) The animals were sacrificed, 
cardiomyocytes were prepared and used for fluorescence microscopy where the localization 
of key proteins implicated in the hypertrophy signalling cascade was monitored. Cell size was 
also determined using light microscopy. 
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Figure 7: Overview of experimental procedures. Standard rat chow (SRC), high caloric diet 
(HCD), End diastolic diameter (EDD), End systolic diameter (ESD), body weight (BW), 
ventricular weight (VW), tibia length (TL), Intraperitoneal (IP), phospho/total (p/t), Glycogen 
synthase kinase (GSK-3), Protein kinase B (PKB/Akt), Glycogen synthase (GS), Nuclear 
Factor of Activated T Cells (NFAT-3) and 2-Deoxy-D-[3H] Glucose (2DG). 
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2.3.1 Biometric determinations  
2.3.1.1 Determination body weight, ventricular weight and visceral fat content 
The body weight, ventricular weight, peritoneal and retroperitoneal fat were recorded as 
described in the experimental overview above. 
2.3.2 Metabolic determinations 
2.3.2.1 Blood glucose 
Fasted plasma glucose concentration was measured using a glucometer (GlucoPlusTM, Montreal, 
Canada) as described in the experimental overview above.  
2.3.2.2 Serum insulin determination: Radioimmunoassay (RIA) 
The Coat-A-Count® (Diagnostic Products Corporation, LA, USA) assay is a solid-phase 
radioimmunoassay (RIA), where radioactive 125I-labeled insulin is used. The insulin in the 
blood sample competes with radiolabelled insulin for binding sites on the insulin-specific 
antibody. This antibody is immobilized to the wall of the polypropylene tubes. Decanting the 
supernatant from the tubes terminates the competition and isolates the antibody bound 
fraction of the radiolabeled insulin. By counting the tubes in the gamma-counter, the presence 
of insulin in the blood sample can be measured against a standard curve. All samples were 
done in duplicate. Prior to the commencement of the assay, all the components of the assay 
were brought to room temperature, as instructed by the manufacturers. Uncoated 12 x 74 mm 
polypropylene tubes were labelled for total count (T) and non-specific binding (NSB) 
respectively.  
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Insulin-antibody coated tubes were labelled for standards (figure 9) and serum sample. 200 
µL of the zero calibrator A was pipetted into the NSB and A tubes. 200 µL of the remaining 
calibrators and serum samples were pipetted in duplicate into the tubes prepared (table 3). 1.0 
ml of 125I insulin (table 3) was added to each tube and subsequently vortexed. Samples were 
incubated for 18 to 24 hours at room temperature and decanted thoroughly. This was done by 
placing each tube (except the total count tube) in a foam decanting rack and allowing the 
tubes to drain for 2 to 3 minutes. Following this, each tube was blotted on absorbent paper 
and to remove the excess moisture a cotton bud was used while avoiding touching the 
antibody coated part of the tube. Removal of excess fluid enhances the precision of the assay. 
The radioactivity of each tube was then measured in a gamma counter (Cobra II Auto 
Gamma, A. D. P, South Africa) for 1 min per tube and the sample antibody binding affinities, 
calculated from the insulin standard curve, which was generated by the gamma counter 
(figure 10). 
 
Table 3: Tabular representation of the calibrators and World Health Organization 
International Reference Preparation (IRP) of Insulin used (code 66/304). 
Calibrator Approximate µIU/ml 1st 
IRP[code: 66/304] 
A 0 
B 5 
C 15 
D 50 
E 100 
F 200 
G 350 
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Figure 8: Schematic representation of tube preparation. 
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Figure 9: Standard curve generated by the gamma-counter 
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2.3.2.3 HOMA-IR index 
HOMA-IR was used to estimate the degree of insulin resistance (Bonora E et al., 2002). A 
low HOMA-IR value indicates high insulin sensitivity and a high HOMA-IR indicates low 
insulin sensitivity/insulin resistance (Bonora E et al., 2002).  
Calculation of Homeostatic model assessment of insulin resistance (HOMA-IR)  
HOMA-IR = fasting plasma glucose level (mmol/l) x fasting serum insulin level (µIU/ml)  ÷ 
22.5 (Matthews DR et al., 1985). 
2.3.3 Preparation of cardiomyocytes  
Adult ventricular cardiomyocytes were prepared from a separate group of animals after a diet 
period of 20 weeks (experimental series two). The cardiomyocytes were isolated from 
untreated control, untreated DIO, treated control +GSK-3 inhibitor and treated DIO + GSK-3 
inhibitor animals. We employed the isolation method previously described by Fischer Y and 
colleagues (1991), which was subsequently modified in our laboratory (Huisamen B et al., 
2001). Hearts were excised from fully anaesthetized animals, and placed in ice-cold Krebs-
Henseleit buffer. After isolation, hearts were cannulated via the aorta and retrogradely 
perfused, at a temperature of 37˚C, with a calcium free HEPES buffer “Solution A” 
containing: 6mM KCl, 1mM Na2HPO4, 0.2mM NaH2PO4, 1.4mM MgSO4, 128mM NaCl, 
10mM HEPES, 5.5mM D-glucose and 2mM pyruvate, pH 7.4, for five minutes to rinse out 
the blood. The perfusate was continually gassed with 100% O2. Thereafter the heart was 
perfused, in a re-circulating fashion, in 50ml HEPES digestion buffer (100ml “Solution B” 
containing: “Solution A” + 0.7% fatty acid free BSA + 1mg/ml collagenase + 18mM 2,3 
butanedione monoxime (BDM)) for 15 min. 50µl of CaCl2 (100mM stock solution) was 
administered at 20 and again at 25 minutes of total perfusion time, respectively. Successful 
digestion was confirmed when perfusate flowed continuously.  
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After digestion, hearts were removed from the perfusion apparatus and the ventricles 
carefully removed from atria. The ventricular tissue was then gently torn apart and incubated 
in a post-digestion buffer (50ml “Solution C” containing: 50% of “Solution A” + 50% of 
“Solution B” + 1% BSA + 1% fatty acid free BSA + 0.2mM CaCl2) for 15 min at 37˚C in a 
shaking water-bath (180 strokes/min). A step-wise administration of calcium for a period of 5 
minutes followed until a final concentration of 1.25mM was reached (4 x 100µl and 1 x 125µl 
of 100mM stock solution CaCl2). Thereafter, the tissue was filtered through a nylon mesh 
(200 x 200µm) and samples were gently subjected to centrifugation at (100 rpm for 3 min). 
The cell pellet was re-suspended in Solution D (“Solution D” containing: “Solution A” + 2% 
fatty acid free BSA + 1.25mM CaCl2) and the cells were allowed to settle for 5 min under 
gravity through the 2% BSA solution into a loose cell pellet. Only live, cardiomyocytes will 
settle. The supernatant, containing dead or dying cells, was aspirated and the cell pellet 
obtained was re-suspended in Solution D and left to stabilize on a slow rotator at room 
temperature for two hours. After the 2 hours had lapsed, the cells were allowed to settle under 
gravity and the supernatant gently removed. The cells were then washed twice with Solution 
E [“Solution E” containing: “Solution A” (minus D-glucose and pyruvate) + 2.0% fatty acid 
free BSA + 1.25mM CaCl2) and allowed to settle under gravity, where after the supernatant 
was removed and the cell pellet used for 2-deoxy-D-[3H] glucose (2DG) uptake experiments 
as discussed below. 
The HEPES, pyruvate and BDM were all obtained from Sigma-Aldrich (St Louis, MO), the 
D-glucose was obtained from Merck (Pty) Ltd - South Africa, the Collagenase Type II was 
purchased from Worthington Biochemical Corporation (Lakewood, NJ) and the BSA was 
obtained from Roche (Cape Town). 
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2.3.4 Determination of 2-Deoxy-D-[3H] Glucose (2DG) uptake by cardiomyocytes  
The ability of the cardiomyocytes to accumulate 2DG was measured as described previously 
by (Fischer Y et al., 1991; Donthi RV et al., 2000 and Huisamen B et al., 2001). The 
cardiomyocyte cell pellet (see above) was suspended in 8ml of Solution E. 500µl of the cell 
suspension containing approximately 0.5µg protein was assayed in a total volume of 750µl. 
An assay in the presence of phloretin (final concentration of 400µM) was included to 
measure non-carrier mediated glucose uptake. The cells were then left to equilibrate for 15 
min in a shaking water bath (180 strokes/minute) at 37 °C. Cells were then stimulated with or 
without 1nM, 10nM or 100nM insulin for 30 minutes. The samples were prepared in 
duplicate. The samples were then incubated with 1.5µCi/ml 2DG (PerkinElmer, Boston) in a 
final concentration of 1.8µM deoxy-glucose for 30 min, to allow for glucose uptake. In order 
to stop carrier-mediated (GLUT1 and GLUT4) glucose uptake 50µl (final concentration of 
400µM) phloretin was added to each sample. Following a 2 min microfuge at 1000 g, this 
2DG containing supernatant was aspirated and cells were washed twice with a basic HEPES 
buffer that contained: 6mM KCl, 1mM Na2HPO4, 0.2mM NaH2PO4, 1.4mM MgSO4, 128mM 
NaCl and 10mM HEPES. The cell pellet was then dissolved in 0.5ml of 1 N NaOH at 70 °C 
in a water bath for 30 to 40 min; where after 0.5ml of dH2O was added. Of this, 2 x 50µl of 
the sample was used for the determination of the protein content using the method of Lowry. 
In order to determine cell-associated radioactivity, the rest of the cell lysate was mixed with 
2ml of scintillation fluid and kept overnight in the dark before counting in a scintillation 
counter (Beckman). 2DG uptake was presented as pmol 2DG/mg protein/30 min.  
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2.3.5 Protein determination Lowry method 
As discussed, 2 x 50µl of the sample dissolved in 0.5N NaOH, was utilized to determine the 
protein content using the Lowry method (Lowry OH et al., 1951). For this method three BSA 
protein standards of known concentration [0.238 mg/ml; 0.476 mg/ml and 0.952 mg/ml] were 
used and 0.5N NaOH was used as the blank. The reaction buffer, which contained 2% 
Na2CO3, 1% CuSO4.5H2O and 2% NaK+ tartrate, was freshly prepared prior to 
experimentation. The assay was done in duplicate and 50µl of blank, standards and samples 
were used to perform the protein assay. 1ml of the reaction medium was added to the blank, 
standards and samples at 10 second intervals, rapidly vortexed and allowed to stand at room 
temperature for 10 min. Afterwards 0.1ml Folin-Ciocalteu’s phenol reagent (1:2 dilution with 
distilled water) was added at the same 10 second intervals, vortexed and allowed to stand for 
30 min. This resulted in a colour development of which the absorbance was read 
spectrophotometrically at 750nm against the blank. The standard curve was used to determine 
the protein concentrations of the samples. 
2.3.6 Indices of cardiac hypertrophy  
2.3.6.1 Ventricular weight to body weight ratio 
At the time of sacrifice, the hearts were rapidly removed and placed in a 4˚C Krebs-Henseleit 
solution to arrest the heart. Both atria were rapidly removed along with the excess non-
cardiac tissue, leaving only the ventricles. The ventricles were blotted on an absorbent paper 
towel, weighed, freeze clamped and stored in liquid nitrogen for biochemical analysis. 
Hypertrophy is indicated by an increase in ventricular weight normalised for body weight 
(ventricular weight/body weight). This method has been used in other publications as a 
measure of hypertrophy (Skoumal R et al., 2004; Asai T et al., 2005). 
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2.3.6.2 Ventricular weight to tibia length ratio 
During the sacrifice, the right hind limb was amputated. This was done close to the hip joint 
in order not to damage the tibia. The tibia was then cleaned, removing all the muscle tissue 
and the length was measured in cm with a calliper. The heart weight was then expressed as a 
ratio to the tibia length. This approach was found to be a more accurate index of cardiac 
hypertrophy than the heart weight-to-body weight ratio in conditions where there are 
fluctuations in body weight (Yin FC et al., 1982; Brede M et al., 2003; and Saupe KW et al., 
2003). 
2.3.7 Lung sampling and determination of the lung fluid content 
After the animals were sacrificed, representative tissue samples were taken from both lungs 
and the wet weight was recorded. The samples were then weighed again after 4-5 days of 
drying at 70˚C. The wet -to-dry weight ratio was calculated as follows: 
w/d= (weight wet –weight dry )/weight wet x 100 (Klinzing S et al., 2000). 
Accumulation of fluid in the lungs is used as an indicator of heart failure. 
2.3.8 In vivo myocardial function 
2.3.8.1 Echocardiography 
After 20 weeks on the feeding program, echocardiography was performed to determine 
cardiac geometry and function. A 5% isoflurane/oxygen mix was used for the induction of 
anaesthesia. The rats were placed on a Deltaphase operating board in a left lateral decubitus 
position. Anaesthesia was maintained with a mixture of 1.5% isoflurane/oxygen. The images 
were acquired with a Siemens Acuson Sequoia 512 Ultrasound system and a 15L8 transducer 
(Siemens, Berlin, Germany) and were analysed at the time of acquisition. This was a blinded 
study, and all studies were performed and interpreted by the same operator. Short-axis 2-
dimensional and M-mode measurements of the LV diameters were taken at the level of the 
papillary muscle and all measurements were averaged over 3 consecutive cardiac cycles. 
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Figure 10 A typical echocardiogram indicating the left ventricular dimensions of the rat 
heart that were ued to determine in vivo myocardial function 
Investigated parameters 
For morphological characterisation of the hearts, the following echocardiographic parameters 
were compared between the different groups. 
(Left ventricular) End-diastolic diameter (EDD) 
(Left ventricular) End-systolic diameter (ESD) 
From these parameters, the LV fractional shortening (in %) was calculated as follows: 
%FS={(EDD – ESD) / EDD} x 100 
After echocardiography, the rats were placed in a cage and allowed to recuperate. 
Stellenbosch University http://scholar.sun.ac.za
47	  
2.3.9 Biochemical analysis  
2.3.9.1 Western Blotting:  
Freeze clamped hearts were used to determine the expression of key proteins in the insulin 
signalling pathway and pathways linked to hypertrophy. 
2.3.9.2 Protein extraction of different tissue fractions 
Cardiac tissue was fractionated into a nuclear, cytosolic and membrane fraction (figure 11). 
The proteins of interest were extracted from the cardiac tissue by means of two lysis buffers 
(lysis buffer with or without Triton X-100) the first buffer contained the following: 20mM 
Tris-HCl (pH 7.5), 1mM EGTA, 1mM EDTA, 1mM NaCl, 1mM β -glycerophosphate, 
2.5mM tetra-sodium-pyrophosphate, 1mM sodium orthovanadate (Na3VO4), 1% Triton X-
100, 10µg/ml leupeptin, 10µg/ml aprotinin and 50µg/ml phenylmethyl sulfonyl fluoride 
(PMSF), while the second buffer did not contain any Triton X-100. Frozen heart tissue (± 
360mg) was pulverized and homogenized, using a Polytron PT-10 homogenizer (2 x 4 sec, 
setting 4) in 0.8ml cold lysis buffer without Triton X-100. The homogenate was left to stand 
on ice for 15 minutes allowing digestive processes to take place. After 15 minutes, the 
homogenate was transferred to Sorvall SS34 rotor centrifuge tubes and samples were 
subjected to centrifugation at 1000 g (2500 rpm) for 10 min at 4°C, where after the 
supernatant (containing cytosolic and membrane fraction) was collected in a separate set of 
Beckmann® TL 50 rotor centrifuge tubes. The pellet containing the nuclear fraction was kept. 
The supernatant (containing the cytosolic and membrane fraction) was then centrifuged, 
using the ultra-centrifuge (Beckmann®, TL 50 rotor centrifuge), at 33 000 rpm for 1 hour. 
The supernatant obtained by this centrifugation contained the cytosolic fraction while the 
pellet contained the membrane fraction. A Bradford (Bradford MM, 1976) protein assay was 
performed on the supernatant to determine the protein content in the samples.  
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To the membrane fraction 200µl of lysis buffer with Triton X-100 was added and a Potter 
Elvehjem Teflon homogeniser used to digest the pellet. 2 x 50µl of the lysate was precipitated 
in 0.5N NaOH, in order to determine the protein content using the Lowry method (Lowry OH 
et al., 1951). Using the pellet from the first centrifugation, 600µl of lysis buffer with Triton 
X-100 was added to the pellet and the contents were transferred to a Potter Elvehjem Teflon 
homogeniser, homogenised five times, transferred to centrifuge tubes, and left on ice for 30 
min. Thereafter, the samples were centrifuged at 15 000 g (13 000 rpm) for 30 min, using the 
Sorvall SS34 rotor. The supernatant contained the nuclear fraction and the pellet was 
discarded. A Bradford protein assay was also performed on this fraction to determine the 
protein content in our samples. 
 
 
 
Figure 11: Schematic representation of fractionation procedure. 
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The Bradford solution contained: 0.6mM Coomassie Brilliant Blue G-250, 95% ethanol and 
85% (w/v) phosphoric acid. Colour development (absorbance) was read 
spectrophotometrically at 595nm against a blank and sample values were determined from a 
standard curve generated from bovine serum albumin (BSA) of known concentrations. This 
sensitive method is suitable for measuring microgram quantities of proteins. Samples for 
Western blotting were diluted in Laemmli sample buffer (4% SDS, 20% glycerol, 10% 2-
mercaptothanol, 0.0004% bromphenol blue and 0.125M Tris-HCl) to contain equal amounts 
of protein per volume unit (Laemmli UK, 1970). The samples were then boiled for 5 minutes 
and aliquots stored at -80°C. 
2.3.9.3 Protein separation 
All stored aliquots were boiled for 5 min and samples were subjected to centrifugation at 
15000rpm for 5 min. 50µg protein was loaded in a stacking polyacrylamide gel and the 
proteins separated according to their molecular weights by a sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS-PAGE) in running buffer. The running buffer 
contained: 50mM Tris, 384mM glycine and 1% SDS. A standard Bio-RAD Mini-Protein III 
system was used. A protein ladder, obtained from Fermentas Life Sciences, was used as 
marker to identify the molecular weights of the proteins of interest. The proteins separated 
within the SDS-gel were then transferred to polyvinylidene fluoride (PVDF) membranes 
(ImmobilonTM P, Millipore) with an applied electrical current of 200V, 200mA for 1 hour, 
in a tank filled with transfer buffer. The transfer buffer consisted of 25mM Tris, 192mM 
glycine and 20% methanol. At the end of the transfer period, the membranes were immersed 
in fresh methanol and left to air dry. This was done so that the membranes could be stained 
with 5% Ponçeau Red in acetic acid (reversible protein stain), for visualization of proteins 
and to confirm whether adequate transfer did occur.  
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Once the Ponçeau Red was rinsed off, the non-specific binding sites on the membranes were 
blocked by gently incubating the membrane in 5% fat-free milk, made up in a TBS-Tween 
solution (Tris-buffered saline (TBS) plus 0.1% Tween 20), for between 1 and 2 hours, at 
room temperature on a shaker. At the end of the blocking period, the membranes were 
thoroughly washed in the TBS-Tween solution. These membranes were then probed with 
primary antibodies directed against: NFAT-3 (Cell Signaling Technology; 1:400), Gata-4 
(Santa Cruz Biotechnology Inc; 1:400), total and phospho-PKB/Akt (Ser473) (Cell Signaling 
Technology; 1:1000) and total and phospho GSK-3 (β-47kDa and α-51kDa) (Cell Signaling 
Technology; 1:1000) and left to incubate overnight at 4°C (membranes were probed for 
phospho protein and stripped to determine total protein expression levels). 
2.3.9.4 Immunodetection of protein 
After the overnight primary antibody incubation, the membranes were thoroughly washed in 
TBS/Tween and incubated in a Horseradish-peroxidase conjugated secondary antibody (from 
donkey), (Amersham Life Science, Sandton, Johannesburg), for 1 hour at room temperature 
on a shaker. This conjugated antibody binds to the already bound primary antibody. To 
remove the excess secondary antibody, the membranes were washed extensively in 
TBS/Tween and kept moist. Proteins were visualized by covering the membrane with 
enhanced chemiluminescence (ECL) detection reagent (Amersham Life Science, Sandton, 
Johannesburg) for 1 minute and then exposing it to an autoradiography film (Hyperfilm ECL, 
RPN 2103). The Horseradishperoxidase reacts with the detection reagent in a luminescence 
reaction and the resulting light emission is captured on the radiography film. Band intensities 
were then densitometrically quantified using UN-SCAN-IT (version 5.1, Silkscience) image 
analysis software. 
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For analysis, all the data was normalised to the untreated condition. In all instances the 
membranes were stripped, by incubating for 5 min in 0.2M NaOH and re-blotted with 
antibody against β -tubulin (Cell Signaling Technology; 1:1000) to verify the uniformity of 
protein loading and the transfer efficiency across the test samples, in instances where there 
was unequal loading these values were not used. 
2.3.10 Immunofluorescence for the detection of NFATc-3 and GATA-4 localization. 
Immunofluorescence is a technique allowing the visualization of a specific protein or antigen 
in cells or tissue sections by binding a specific antibody chemically conjugated with a 
fluorescent dye such as fluorescein isothiocyanate (FITC). There are two major types of 
immunofluorescence staining methods: 1) direct immunofluorescence staining in which the 
primary antibody is labelled with fluorescence dye, and 2) indirect immunofluorescence 
staining in which a secondary antibody labelled with fluorochrome is used to recognize a 
primary antibody (Rosendal S and Black FT, 1972).  
In our experiment the indirect immunofluorescence method was used to visualise NFATc3 
and GATA-4 distribution and localisation in cardiomyocytes in our model of diet induced 
obesity and insulin resistance. For this technique, cardiomyocytes were prepared as described 
previously. After the resting period the cells were plated in laminin coated 6 well plates. A 
concentration of 10.0mg/cm2 was used and the plates were left for a period of 2-3 hours (Bird 
SD et al., 2003). The laminin facilitates cardiomyocyte attachment. After this time had 
elapsed, Solution E was removed (see p 42) and the monolayer of cells was washed twice 
with sterile PBS (0.1M). A 1:1 ratio of the fixative methanol/acetone (1ml/coverslip) was 
added, and incubated at 4ºC for 10 minutes. The fixative was subsequently removed and cells 
were air dried for 20 minutes at room temperature. Cells were rinsed with PBS and the 
coverslips were then transferred onto temporary microscope slides. 100µl 5% donkey serum 
was added for 20 minutes at room temperature.  
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After draining the serum, 100µl primary antibody was added. In this particular case, the 
following primary antibodies were used NFATc3 (Santa Cruz Biotechnology Inc) (source: 
goat polyclonal antibody, 1:50 dilution) and GATA-4 (Santa Cruz Biotechnology Inc) 
(source: rabbit polyclonal antibody, 1:200 dilution) (Tokudome T et al., 2005) while PBS 
was added to the controls. This was incubated overnight at 4ºC. The primary antibody 
solution was removed and the cells were once again rinsed carefully with PBS. The cells 
were then incubated with 100µl of a Donkey anti-goat FITC (green) (Santa Cruz 
Biotechnology Inc) and Donkey anti-rabbit Texas Red (Santa Cruz Biotechnology Inc) 
conjugated secondary antibody solution (1:200 dilution) (Tokudome T et al., 2005), where 
the former was directed against NFATc3 and the latter against GATA-4, for 30 minutes at 
room temperature. In addition, 100µl Hoechst 33342 (1:200) dye was added for a further 10 
minutes. The cells were finally washed 3 times with PBS and mounted on permanent 
microscope slides. The serum, primary and secondary antibodies and Hoechst dye were made 
up with sterile PBS. Image acquisition was performed on an Olympus Cell® system attached 
to an IX 81 Inverted fluorescence microscope equipped with a F-view-II cooled CCD camera 
(Soft Imaging Systems). Using a Xenon-Arc burner (Olympus Biosystems GMBH) as light 
source, images were acquired using the 360nm, 472nm or 572nm excitation filter. Emission 
was collected using a UBG triple-bandpass emission filter cube (Chroma). Images were 
acquired through z-stacks, using an Olympus Plan Apo N60x/1.4 Oil objective. Four random 
areas within each image were taken to depict the localization of NFATc3 and GATA-4. The 
scale used was 0.002nm for high magnification and 0.2nm for lower magnification.  
  
Stellenbosch University http://scholar.sun.ac.za
53	  
2.3.11 Light microscopy for cell size determination  
For cell width determination the images were acquired using the same Olympus Cell® 
system. An inverted light microscope equipped with a F-view-II cooled CCD camera (Soft 
Imaging Systems) was used on the fixed cells that were prepared for the immunofluorescence 
experiment described above. Approximately 60-80% of the cells on the cover slips were rod-
shaped cardiac myocytes. Between 40-50 cells were selected from each group (n=2-3), using 
3 different planes. Using the program, Act2U (Ver. 1.70 Nikon Corporation, Japan), the 
width of each cell was measured diagonally from a visible nucleus.  
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2.4 Statistical analysis  
All data were presented as mean ± standard error of the mean (SEM), unless otherwise stated. 
When comparisons between two groups were made, the two-tailed unpaired Student t-test 
was used. For multiple group comparisons 2 way-ANOVA followed by a Bonferroni post-
hoc test was used. p < 0.05 was considered as statistically significant. All statistical analysis 
of data was performed using GraphPad Prism 5®. 
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3 CHAPTER 3: RESULTS 
 
 
3.1 Biometric and metabolic data of 20 week untreated and treated control, 
untreated and treated DIO animals 
Table 4: Biometric and metabolic data of 20 week untreated and treated control, untreated 
and treated DIO animals. All values are expressed as mean ±SEM. n=5-6; 
#p<0.05;*p<0.005; ǂp<0.0005; ¥p<0.01; +p<0.001 
 Control DIO 
 Untreated Treated Untreated Treated 
Body weight (g) 402±11  447±11 # 529±26 * 529±18 
Ventricular weight (g) 0.983±0.030 1.075±0.022 # 1.158±0.029 * 1.127±0.045 
Intraperitoneal fat (g) 16.6±1.7 18.8±1.9 35.5±3.7 + 36.2±3.2 
Glucose (mmole/L) 5.52±0.34 5.43±0.32 6.68±0.37 # 5.82±0.42 
Serum insulin (pmoe/L) 17.12±0.80 28.18±3.36 ¥ 32.91±2.8 
‡ 22.93±1.62 # 
HOMA 4.20±0.31 6.64±1.04 ¥ 7.54±1.63 + 7.08±1.64 
 
After 20 weeks on the respective diets, (i) the DIO rats were significantly heavier than their 
age-matched control counterparts (529±26 g vs. 402±11 g; *p<0.005). This obese state was 
also associated with a significant increase in (ii) the ventricular weight (1.158±0.029 g vs. 
0.983±0.030 g; *p<0.005), (iii) intraperitoneal fat mass (35.5±3.7 g vs. 16.6±1.7 g; +p<0.001), 
(iv) fasted blood glucose (6.68±0.37 mmol/L vs. 5.52±0.34 mmol/L; #p<0.05), and (v) serum 
insulin levels (32.91±2.8 pmol/L vs. 17.12±0.80 pmol/L; ǂp<0.0005). (vi) The mean HOMA 
index of the DIO animals was also significantly greater when compared to the controls 
(7.54±1.63 vs. 4.20±0.31; +p<0.001). This data suggests that the DIO animals developed 
insulin resistance during this 20 week high caloric feeding programme.  
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The GSK-3 inhibitor treatment (i) increased the body weight significantly in the controls 
(treated control 447±11 g vs. untreated control 402±11 g; #p<0.05), however it had no 
significant effect on the body weight of the DIO animals (treated DIO 529±18 g vs. untreated 
DIO 529±26 g). (ii) The ventricular weight was significantly higher in the treated controls vs. 
their untreated control counterparts (treated control 1.075±0.022 g vs. untreated control 
0.983±0.030 g; #p<0.05). This increase in ventricular weight was, however, not evident in the 
treated DIO animals vs. the untreated DIO counterparts (treated DIO 1.127±0.045 g vs. 
untreated DIO 1.158±0.029 g). (iii) The GSK-3 inhibitor treatment did not influence the 
intraperitoneal fat mass in the controls (untreated control 16.6±1.7 g vs. treated control 
18.8±1.9 g), nor the DIO animals (untreated DIO 35.5±3.7 g vs. treated DIO 36.2±3.2 g). (iv) 
The GSK-3 inhibitor treatment had no significant effect on fasted blood glucose levels both 
in the controls (treated control 5.43±0.32 mmol/L vs. untreated control 5.52±0.34 mmol/L) 
and DIO animals (treated DIO 5.82±0.43 mmol/L vs. untreated DIO 6.68±0.36 mmol/L). (v) 
The GSK-3 inhibitor treatment increased fasted serum insulin levels significantly in the 
controls (treated control 28.18±3.36 pmol/L vs. untreated control 17.12±0.80 pmol/L; 
¥p<0.01) and decreased the fasted serum insulin levels of the DIO animals significantly 
(treated DIO 22.93±1.62 pmol/L vs. untreated DIO 32.91±2.77 pmol/L; #p<0.05). (vi) The 
mean HOMA index in the treated controls was significantly larger than in the untreated 
controls (treated control 6.64±1.04 vs. untreated control 4.20±0.31; ¥p<0.01). In the treated 
DIO animals the GSK-3 inhibitor treatment had no significant effect on the mean HOMA 
index (treated DIO 7.08±1.64 vs. untreated DIO 7.54±1.63). 
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3.2 Cardiomyocyte preparation and glucose uptake 
3.2.1 Basal glucose uptake by cardiomyocytes  
At basal levels, the diet had no significant effect on glucose uptake in cardiomyocytes 
prepared from the control and DIO animals (control 15.08±1.26 pmol/mg protein/30min vs. 
DIO11.43±1.01 pmol/mg protein/30min). The GSK-3 inhibitor treatment also had no 
significant effect in the control animals (treated control 19.83±4.02 pmol/mg protein/30min  
vs. untreated control 15.08±1.26 pmol/mg protein/30min) and DIO animals (treated DIO 
17.72±3.13 pmol/mg protein/30min vs. untreated DIO 11.43±1.01 pmol/mg protein/30min). 
  
Figure 12: Insulin-stimulated 2-deoxy-[3H]-glucose accumulation by isolated 
cardiomyocytes prepared from untreated and treated control and DIO animals. A 
concentration range from 1nM to 100nM insulin was used. All values are expressed as mean 
±SEM. n=5; #p<0.05.  
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3.2.2 Glucose uptake by cells after insulin stimulation at different concentrations 
3.2.2.1 Stimulation with 1nM insulin 
When the cardiomyocytes were stimulated with insulin at concentrations of 1nM, there was a 
decrease in the insulin sensitivity of the cardiomyocytes prepared from DIO animals (DIO 
16.81±1.61 pmol/mg protein/30min vs. control 25.06±3.46 pmol/mg protein/30min) 
noticeable, however, this decrease was not significant. The GSK-3 inhibitor treatment had no 
significant effect on glucose uptake in the control animals (treated control 30.79±6.26 
pmol/mg protein/30min vs. untreated control 25.06±3.46 pmol/mg protein/30min) and DIO 
animals (treated DIO 25.89±5.67 pmol/mg protein/30min vs. untreated DIO 16.81±1.61 
pmol/mg protein/30min). 
3.2.2.2 Stimulation with 10nM insulin 
When the cardiomyocytes were stimulated with insulin at concentrations of 10nM, the cells 
prepared from DIO animals had a significantly impaired response to insulin compared to the 
control animals (DIO 20.00±1.76 pmol/mg protein/30min vs. control 29.80±2.76 pmol/mg 
protein/30min; #p<0.05). The GSK-3 inhibitor treatment had no significant effect on glucose 
uptake in the control animals (treated control 30.45±8.41 pmol/mg protein/30min vs. 
untreated control 29.80±2.76 pmol/mg protein/30min). In the DIO animals the GSK-3 
inhibitor treatment increased glucose uptake (treated DIO 36.61±6.84 pmol/mg 
protein/30min vs. untreated DIO 20.00±1.76 pmol/mg protein/30min), however, this increase 
was not significant. Despite the fact that the increases in insulin stimulated glucose uptake 
was not significant in either of the treatment groups when compared to cells from untreated 
animals, a 2-way ANOVA showed a significant overall effect of the treatment (p<0.05).  
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3.2.2.3 Stimulation with 100nM insulin 
When the cardiomyocytes were stimulated with insulin at concentrations of 100nM, the cells 
prepared from DIO animals had a significantly impaired response to insulin compared to the 
control animals (DIO 20.19±1.78 pmol/mg protein/30min vs. control 37.48±4.46 pmol/mg 
protein/30min; #p<0.05). The GSK-3 inhibitor treatment had no significant effect on glucose 
uptake in the control animals (treated control 43.41±7.52 pmol/mg protein/30min vs. 
untreated control 37.48±4.46 pmol/mg protein/30min). In the treated DIO animals there was 
a significant increase in glucose uptake (treated DIO 43.07±7.27 pmol/mg protein/30min vs. 
untreated DIO 20.19±1.78 pmol/mg protein/30min; #p<0.05) after stimulation with 100nM of 
insulin. At this concentration a 2-way ANOVA showed a significant overall effect of the 
treatment (p<0.05) on insulin stimulated glucose uptake.  
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3.3 Indices of myocardial hypertrophy 
3.3.1 VW/BW ratio  
 
Figure 13: VW/BW ratio of 20 week untreated and treated control and treated DIO animals. 
All values are expressed as mean ±SEM. VW-ventricular weight, BW-body weight n=6; 
#p<0.05 
There was a significant difference in the VW/BW ratio between the control vs. DIO rats 
(2.45x10-3±6.67x10-5 vs. 2.21x10-3±5.40x10-5; #p<0.05). The GSK-3 inhibitor treatment had 
no significant effect on the VW/BW ratio in the controls (treated control 2.41x10-3±2.94x10-5 
vs. untreated control 2.45x10-3±6.67x10-5) and in the DIO animals (treated DIO 
2.13x103±2.30x10-5 vs. untreated DIO 2.21x10-3±5.40x10-5). 
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3.3.2 VW/TL ratio 
 
Figure 14: VW/TL ratio of 20 week untreated and treated control and treated DIO animals. 
All values are expressed as mean ±SEM. VW-ventricular weight, TL-Tibia length n=6; 
¥p<0.01 
There was a significant difference in the VW/TL ratio between the control vs. DIO rats 
(0.242±0.007 vs. 0.276± 0.007; ¥p<0.01). This finding indicates that after 20 weeks on the 
diet, the hearts from the DIO rats had developed myocardial hypertrophy. The GSK-3 
inhibitor treatment had no significant effect on the VW/TL ratio in the controls (treated 
control 0.263±0.009 vs. untreated control 0.242±0.007), nor in the DIO animals (treated DIO 
0.272±0.010 vs. untreated DIO 0.276±0.007). 
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3.4 Lung fluid content 
 
Figure 15: Lung fluid content of 20 week untreated and treated control and treated DIO 
animals. All values are expressed as mean ±SEM. n=6 
There were no significant differences in the lung fluid content of 20 week control vs. DIO 
rats (74.96±0.75 % vs. 74.40±0.72 %). The GSK-3 inhibitor treatment also had no significant 
effect on lung fluid content in the controls (treated control 75.54±0.53 % vs. untreated control 
74.96±0.75 %), nor DIO animals (treated DIO 73.17±1.27 % vs. untreated DIO 
74.40±0.72 %). 
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3.5 In vivo myocardial function 
3.5.1 Echocardiography 
Table 5: Echocardiography data of 20 week untreated and treated control, untreated and 
treated DIO animals. All values are expressed as mean ±SEM. % Fractional shortening (FS), 
End systolic diameter (ESD), End diastolic diameter (EDD). n=6;# p<0.05 
 Control DIO  
 Untreated Treated Untreated Treated N 
ESD (mm) 3.89±0.16 4.06±0.14 4.26±0.13 4.35±0.15 6 
EDD (mm) 8.15±0.10 8.63±0.007 # 8.48±0.11 # 8.72±0.15 6 
%FS 52.28±1.55 53.06±1.28 49.81±1.24 49.97±1.33 6 
 
There were no significant differences in ESD in control vs. DIO rats (3.89±0.16 mm vs. 
4.26±0.13 mm), however, there was a significant difference in EDD in the control vs. DIO 
animals (8.15±0.10 mm vs. 8.48±0.11 mm; #p<0.05). The GSK-3 inhibitor treatment had no 
significant effect on ESD in the controls (untreated control 3.89±0.16 mm vs. treated control 
4.06±0.14 mm) or in the DIO animals (treated DIO 4.35±0.15 mm vs. untreated DIO 
4.26±0.13 mm). EDD was significantly increased in the treated controls (treated control 
8.63±0.07 mm vs. untreated control 8.15±0.10 mm; #p<0.05), however, there were no 
significant differences in EDD in the treated DIO animals (treated DIO 8.72±0.15 mm vs. 
untreated DIO 8.48±0.11 mm). There was a decrease in %FS in the control vs. DIO animals 
(52.28±1.55 % vs. 49.81±1.24 %), however, this decrease was not significant. This data 
indicates that the diet had no pronounced adverse effects on myocardial function in vivo in 
the DIO animals. The GSK-3 inhibitor treatment had no significant effect on %FS in the 
controls (untreated control 52.28±1.55 % vs. treated control 53.06±1.28 %), nor in the DIO 
animals (treated DIO 49.97±1.33 % vs. untreated DIO 49.81±1.24 %). 
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3.6 Biochemical Analysis: 
3.6.1  Insulin signalling pathway 
3.6.1.1 PKB/Akt 
 
 
 
 
 
 
Figure 16: Phospho and Total PKB/Akt expression levels of hearts from control vs. DIO rats. 
No cross comparisons were made between blots. All values expressed as mean ± SEM. n=6; 
¥p<0.01 
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The total PKB/Akt expression levels were significantly higher in the DIO animals (DIO 
124.0±7.1 % vs. control 100±4.9 %; ¥p<0.01). The phospho-PKB/Akt (Ser473) was 
significantly decreased in the DIO animals (DIO 86.2±3.9 % vs. control 100±3.1 %; ¥p<0.01). 
 
Figure 17: Phospho/total PKB/Akt expression levels of hearts from control vs. DIO animals. 
All values expressed as mean ± SEM. n=6; +p<0.001 
The ratio of phosphorylated vs. total PKB/Akt was significantly reduced in hearts from the 
DIO animals (DIO 58.3±3.6 % vs. control 83.5±5.3 %; +p<0.001) compared to their control 
counterparts, thus less total PKB/Akt was phosphorylated in this group.  
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Figure 18: Phospho and Total PKB/Akt expression levels of hearts from untreated vs. treated 
control. No cross comparisons were made between blots. All values expressed as mean ± 
SEM. n=6; €p<0.0001 
There were no significant differences in total PKB/Akt expression levels in hearts from the 
untreated vs. treated control animals (untreated control 100.0±1.2 % vs. treated control 
94.6±2.5 %). The phospho-PKB/Akt (Ser473) was significantly decreased in hearts from the 
treated control animals (treated control 53.4±4.7 % vs. untreated control 100±1.7 %; 
€p<0.0001). 
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Figure 19: Phospho/total PKB/Akt expression levels of hearts from untreated vs. treated 
control animals. All values expressed as mean ± SEM. n=6; +p<0.001 
The ratio of phosphorylated vs. total PKB/Akt was significantly reduced in the treated control 
animals (treated control 38.7±3.9 % vs. untreated control 72.4±7.4 %; +p<0.001) compared to 
their untreated control counterparts, thus less total PKB/Akt was phosphorylated in this group.  
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Figure 20: Phospho and Total PKB/Akt expression levels of hearts from untreated vs. treated 
DIO animals. No cross comparisons were made between blots. All values expressed as mean 
± SEM. n=6 
There were no significant differences in total (untreated DIO 100.0±6.2 % vs. treated DIO 
102.6±2.6 %) and phospho-PKB/Akt (Ser473) (untreated DIO 100.0±3.3 % vs. treated DIO 
100±5.5 %) expression levels in hearts from the untreated DIO vs. treated DIO. 
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Figure 21: Phospho/total PKB/Akt expression levels of hearts from untreated vs. treated DIO 
animals. All values expressed as mean ± SEM. n=6 
There were no significant differences in the ratio of phosphorylated vs. total PKB/Akt in the 
hearts from untreated DIO vs. treated DIO animals (untreated 52.9±3.5 % vs. treated DIO 
50.9±3.3 %). 
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3.6.1.2 GSK-3β 
 
 
 
 
 
Figure 22: Phospho and Total GSK-3β expression levels of hearts from control vs. DIO 
animals. No cross comparisons were made between blots. All values expressed as mean ± 
SEM. n=6; +p<0.001 
There were no significant differences in total GSK-3β expression levels in hearts from 
control vs. DIO animals (control 100±6.2 % vs. DIO 83.2±9.3 %). The phospho-GSK-3β 
(Ser9) was significantly decreased in the DIO animals (DIO 54.9±9.9 % vs. control 
100±6.4 %; +p<0.001). 
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Figure 23: Phospho/total GSK-3β expression levels of hearts from control vs. DIO animals. 
All values expressed as mean ± SEM. n=6 
There were no significant differences in the ratio of phosphorylated vs. total GSK-3β 
between hearts from control vs. DIO animals (control 35.4±1.2 % vs. DIO 26.6±7.7 %). 
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Figure 24: Phospho and Total GSK-3β expression levels of hearts from untreated vs. treated 
control animals. No cross comparisons were made between blots. All values expressed as 
mean ± SEM. n=6; #p<0.05; ¥p<0.001 
Total GSK-3β expression levels were significantly decreased in the hearts from treated 
control vs. untreated control counterparts (treated control 86.6±2.3 % vs. untreated control 
100±3.1 %; #p<0.05), where as the phospho-GSK-3β (Ser9) was significantly increased in the 
hearts from treated control animals (treated control 109.2±1.6 % vs. untreated control 
100±1.7 %; ¥p<0.001). 
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Figure 25: Phospho/total GSK-3β expression levels of hearts from untreated vs. treated 
control animals. No cross comparisons were made between blots. All values expressed as 
mean ± SEM. n=6; ǂp<0.0005 
The ratio of phosphorylated vs. total GSK-3β was significantly increased in hearts from the 
treated control animals (treated control 91.6±3.5 % vs. untreated control 72.5±1.4 %; 
ǂp<0.0005) compared to their untreated counterparts, thus more GSK-3β was phosphorylated 
in this group.  
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Figure 26: Phospho and Total GSK-3β expression levels of hearts from untreated vs. treated 
DIO animals. No cross comparisons were made between groups. All values expressed as 
mean ± SEM. n=6; ¥p<0.01 
There were no significant differences in total GSK-3β expression levels in the hearts from 
untreated DIO vs. treated DIO animals (untreated DIO 100.0±2.4 % vs. treated DIO 
94.9±3.2 %). Phospho-GSK-3β (Ser9) expression levels were significantly decreased in hearts 
from the treated DIO animals when compared to their untreated counterparts (treated DIO 
68.7±9.4 % vs. untreated DIO 100±3.7 %; ¥p<0.01). 
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Figure 27: Phospho/total GSK-3β expression levels of hearts from untreated vs. treated DIO 
animals. All values expressed as mean ± SEM; #p<0.05; n=3 
There was a significant differences in the ratio of phosphorylated vs. total GSK-3β in the 
hearts from untreated DIO vs. treated DIO animals (untreated 37.5±1.4 % vs. treated DIO 
27.2±3.9 %; #p<0.05), thus less GSK-3β was phosphorylated in hearts from the treated DIO 
group. 
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3.6.2 Key proteins in pathways that mediate myocardial hypertrophy 
3.6.2.1 NFAT-3 expression levels  
 
 
 
 
 
Figure 28: NFAT-3 expression levels in the cytosolic and nuclear fraction of hearts from 
control vs. DIO animals. All values expressed as mean ± SEM; ¥p<0.01; n=7-9 	  
The total NFAT-3 expression levels were significantly higher in the cytosolic fraction than in 
the nuclear fraction in the hearts from control (cytosolic control 100±5.1 % vs. nuclear 
control 76.7±2.3 %; ¥p<0.01) and DIO animals (cytosolic DIO 91.1±1.9 % vs. nuclear DIO 
74.8±2.1 %; ¥p<0.01). 
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Figure 29: NFAT 3 expression levels in the cytosolic and nuclear fraction of hearts from 
untreated vs. treated control animals. All values expressed as mean ± SEM; *p<0.05; n=7-9 
The total NFAT-3 expression levels were significantly higher in the cytosolic fraction than in 
the nuclear fraction in hearts from the untreated control animals (untreated cytosolic control 
100±2.6 % vs. untreated nuclear control 80.1±3.2 %; *p<0.05). In hearts from the treated 
control animals total NFAT-3 expression levels were decreased in the cytosolic fraction and 
increased in the nuclear fraction (treated cytosolic control 131.0±7.9 % vs. treated nuclear 
control 145.6±1.6 %), however, this nuclear import was not significant.   
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Figure 30: NFAT 3 expression levels in the cytosolic and nuclear fraction of hearts from 
untreated vs. treated DIO animals. All values expressed as mean ± SEM; *p<0.05; n=7-9 
The total NFAT-3 expression levels were significantly higher in the cytosolic fraction than in 
the nuclear fraction in the hearts of untreated DIO animals (untreated cytosolic DIO 100±4.3 % 
vs. untreated nuclear DIO 78.0±1.5 %; *p<0.05). In hearts from the treated DIO animals total 
NFAT-3 expression levels were decreased in the cytosolic fraction and increased in the 
nuclear fraction (treated cytosolic DIO 102.7±1.0 % vs. treated nuclear DIO 107.6±7.9 %), 
however, this nuclear import was also not significant.  
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3.6.2.2 GATA -4 expression levels 
 
 
 
 
 
Figure 31: GATA-4 expression levels in the cytosolic and nuclear fraction of hearts from 
control vs. DIO animals. All values expressed as mean ± SEM; n=7-9 
The total GATA-4 expression levels were significantly lower in the nuclear fraction than in 
the cytosolic fraction in hearts from the control (cytosolic control 100±3.1 % vs. nuclear 
control 78.8±3.6 %; ¥p<0.01) and DIO animals (cytosolic DIO 100.8±2.7 % vs. nuclear DIO 
63.9±6.6 %; ¥p<0.01) with no differences between the levels in control and DIO rat hearts. 
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Figure 32: GATA-4 expression levels in the cytosolic and nuclear fraction in hearts of 
untreated vs. treated control animals. All values expressed as mean ± SEM; *p<0.05; n=7-9 
The total GATA-4 expression levels were significantly higher in the cytosolic fraction than in 
the nuclear fraction in the hearts from untreated control animals (untreated cytosolic control 
100±3.9 % vs. untreated nuclear control 87.1±4.3 %; *p<0.05). In hearts from the treated 
control animals total GATA-4 expression levels were increased in the cytosolic fraction and 
decreased in the nuclear fraction (treated cytosolic control 79.6±3.3 % vs. treated nuclear 
control 72.4±1.0 %), however, this nuclear import was also not significant.   
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Figure 33: GATA-4 expression levels in the cytosolic and nuclear fraction of hearts from 
untreated vs. treated DIO animals. All values expressed as mean ± SEM; *p<0.05; n=7-9 
The total GATA-4 expression levels were significantly higher in the cytosolic fraction than in 
the nuclear fraction in the hearts from untreated DIO animals (untreated cytosolic DIO 
100±4.8 % vs. untreated nuclear DIO 81.0±5.3 %; *p<0.05). In hearts from the treated DIO 
animals total GATA-4 expression levels were decreased in the cytosolic fraction and 
increased in the nuclear fraction (treated cytosolic DIO 80.5±8.2 % vs. treated nuclear DIO 
103.0±10.5 %), however, this nuclear import of GATA-4 was not significant.  
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3.7 Immunofluorescence 
 
    
    
 
Figure 34: Images of cardiomyocytes were acquired with a 20 x (A) and 60 x (A 1) oil 
immersion objective (scale bar, 200µm and 20µm respectively). Figure A shows the low 
magnification (scale bar 200µm) and A1 shows the high magnification (20µm) of 
cardiomyocytes from untreated control animals. The images show the signal from: (1) 
Hoescht, a nuclear stain (2) NFATc3 coupled to FITC, displayed in green, (3) GATA-4 
coupled to Texas Red, displayed in red and (4) co localisation are NFATc3 and GATA-4, 
displayed in yellow. The images given are representative of  experiments on 3 individual 
hearts in each group. 
 
In cardiomyocytes from the untreated controls both NFATc3 and GATA-4 were evenly 
distributed in the cytoplasm as shown in figure 34. 
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Figure 35: Images of cardiomyocytes were acquired with a 20 x (B) and 60 x (B 1) oil 
immersion objective (scale bar, 200µm and 20µm respectively). Figure B shows the low 
magnification (scale bar 200µm) and B1 shows the high magnification (20µm) of 
cardiomyocytes from untreated DIO animals. The images show the signal from: (1) Hoescht, 
a nuclear stain (2) NFATc3 coupled to FITC, displayed in green, (3) GATA-4 coupled to 
Texas Red, displayed in red and (4) co localisation are NFATc3 and GATA-4, displayed in 
yellow. The images given are representative of experiments on 3 individual hearts in each 
group. The white arrows indicate nuclear localization of NFATc3. 
 
In cardiomyocytes from the untreated DIO animals, both at low and at high magnification, 
NFATc3 was localized in the perinuclear area of the cytoplasm as indicated by the white 
arrows, but this phenomenon was only seen in some cells. GATA-4 was once again more 
evenly distributed in the cytoplasm as shown in figure 35. 
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Figure 36: Images of cardiomyocytes were acquired with a 20 x (C) and 60 x (C 1) oil 
immersion objective (scale bar, 200µm and 20µm respectively). Figure C shows the low 
magnification (scale bar 200µm) and C1 shows the high magnification (20µm) of 
cardiomyocytes from treated control animals. The images show the signal from: (1) Hoescht, 
a nuclear stain (2) NFATc3 coupled to FITC, displayed in green, (3) GATA-4 coupled to 
Texas Red, displayed in red and (4) co localisation are NFATc3 and GATA-4, displayed in 
yellow. The images given are representative of experiments on 3 individual hearts in each 
group. The white arrows indicate nuclear localization of NFATc3 and GATA-4. 
 
In the cardiomyocytes from treated control animals, both at low and at high magnification, 
NFATc3 and GATA-4 were localized in the perinuclear area of the cytoplasm as indicated by 
the white arrows, but this phenomenon was only seen in some cells as shown in figure 36. 
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Figure 37: Images of cardiomyocytes were acquired with a 20 x (D) and 60 x (D 1) oil 
immersion objective (scale bar, 200µm and 20µm respectively). Figure D shows the low 
magnification (scale bar 200µm) and C1 shows the high magnification (20µm) of 
cardiomyocytes from treated DIO animals. The images show the signal from: (1) Hoescht, a 
nuclear stain (2) NFATc3 coupled to FITC, displayed in green, (3) GATA-4 coupled to Texas 
Red, displayed in red and (4) co localisation are NFATc3 and GATA-4, displayed in yellow. 
The images given are representative of experiments on 3 individual hearts in each group. The 
white arrows indicate nuclear localization of NFATc3 and GATA-4. 
 
In the cardiomyocytes from treated DIO animals, both at low and at high magnification, 
NFATc3 and GATA-4 were localized in the perinuclear area of the cytoplasm as indicated by 
the white arrows, but this phenomenon was only seen in some cells as shown in figure 37. 
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3.8 Light microscopy: determination of cell width 
 
    .. 
   
 
 
 
Figure 39: Cell width (µm) of cardiomyocytes isolated from Control vs. DIO animals and the 
effect of treatment. All values are expressed as mean ±SEM. ¥p<0.01; €p<0.0001; n=2-3 
individual preparations 
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Figure 38: Representative cardiomyocytes 
images showing cell width as determined 
by light microscopy from control, DIO, 
treated control and treated DIO hearts. 
The images were acquired with a 60 x oil 
immersion objective (scale bar 20µm). 40-
50 cells, on 3 different planes were 
selected from each group.	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There was a significant increase (figure 39) in the cardiomyocyte cell width (µm) of control 
vs. DIO rats (24.55±0.97 µm vs. 45.37±2.31	   µm; €p<0.0001), indicating concentric 
hypertrophy. The GSK-3 inhibitor treatment also increased cardiomyocyte cell width 
significantly in the control animals (treated control 33.89±1.42 µm vs. untreated control 
24.55±0.97 µm; €p<0.0001). The cell width in the treated DIO animals was significantly 
decreased compared to the untreated DIO animals (treated DIO 37.12±2.19 µm vs. untreated 
DIO 45.37±2.31 µm; ¥p<0.01). 
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4 CHAPTER 4: DISCUSSION 
 
 
4.1 Characterisation of the model 
The primary aims of the current study were to document the progression of myocardial 
hypertrophy induced in a rat model of diet induced obesity leading to pre-diabetes and to 
assess how inhibition of the GSK-3 protein affects this process in both the normal and pre-
diabetic animals. We successfully utilized the model of diet induced obesity, which is 
characterized by “hyperphagia, increased thermogenesis, hyperleptinaemia and mild insulin 
resistance” (Pickavance LC et al., 1999). This model has been characterized in our laboratory 
and shown to be physiologically relevant and comparable to the human equivalent of insulin 
resistance as a result of obesity (Du Toit EF et al., 2005). The choice of a non-diabetic model 
was based on the premise that in the diabetic state, a difference in glycemic control between 
placebo and drug-treated animals constitutes a confounding factor for food intake and plasma 
volume regulation.  
4.2 Effect of the diet 
4.2.1 Biometric and metabolic data 
A feeding period of 20 weeks was chosen, as opposed to the 16 weeks usually employed in 
our laboratory, in order to document the progression of obesity on certain biometric and 
metabolic parameters. Furthermore, this time period was chosen in order to ensure that 
hypertrophy was well pronounced in our model of diet induced obesity.  
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The main findings on the biometric and metabolic parameters were as follows: The high 
caloric diet (HCD) used in this present study was of sufficient intensity and duration to 
promote obesity in the DIO rats. These rats had a significant increase in body weight (table 4) 
and intra-peritoneal fat mass (table 4) compared to their control litter mates. Moreover, we 
also observed complications associated with obesity, such as impaired glucose tolerance 
(table 4) and hyperinsulinemia (table 4), which are associated with the insulin resistant state. 
These results are in agreement with other studies where obesity was induced in rats using a 
high caloric diet. Cerf ME et al. (2007) found that prolonged feeding with fat-enriched diets 
induces an increase in body weight in susceptible rats in the range of 10% to 20% over 
standard rat chow (SRC) controls. Furthermore, Du Toit EF et al. (2005) found that the HCD 
animals consumed more energy per day (table 1) compared to their age matched control 
counterparts. The increase in food intake between the HCD and SRC fed rats could be due to 
the increased palatability of the HCD, which promotes hyperphagia (Cerf ME et al., 2005; 
Du Toit EF et al., 2005), as the HCD consists of moist, sweet pellets, while the SRC, 
received by the control animals, is made up of dry pellets. As a measure of obesity, the 
intraperitoneal fat mass was used. The measurement of this adipose tissue has been used 
previously as a measure of body fat (De Freitas Mathias PC et al., 2007). An increase in 
intraperitoneal fat has been shown to play a significant role in the development of insulin 
resistance.  
The proposed mechanism is that large visceral fat masses imply hypertrophy of the adipose 
tissue. These adipose tissues then release excessive amounts of FFA (Hutley L and Prins JB, 
2005) and adipocyte-derived peptides (Vázquez-Vela ME, 2008) in the circulation, which 
incites lipotoxicity (Hutley L and Prins JB, 2005). The resulting lipotoxicity affects adipose 
as well as non-adipose tissue, resulting in excess fat being deposited in ectopic tissue such as 
liver, skeletal muscle, pancreas and the heart.  
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This contributes to the development of hypertriglyceridemia and hyperglycemia in the liver, 
muscle and pancreas and results in insulin resistance in the heart (Boden G et al., 1994; Pan 
DA et al., 1997; Eckel J and Reinauer H, 1990; Eckel RH et al., 2005; Unger RH, 1995; 
Belfort R et al., 2005). The observed complications associated with obesity, such as 
hyperinsulinemia, were also reported by Hallfrisch J et al. (1981), where they found that 
sucrose and high-fat feeding for eight to nine weeks resulted in euglycemia, but with 
increased circulating insulin concentrations. Obese individuals may exhibit euglycemia due 
to the sufficient production of insulin, but suffer from insulin resistance in the peripheral 
tissues such as muscle, liver and adipose tissue (Sesti G, 2006). Hyperglycemia arises at a 
later stage, when the pancreas reaches its capacity to overproduce insulin, and this then leads 
to elevated fasting blood glucose concentrations and impaired glucose tolerance (Sesti G, 
2006; Thévenod F, 2008). The HOMA-IR model for the assessment of insulin resistance is 
commonly used as a tool for measuring the degree of insulin resistance. A low HOMA-IR 
value indicates high insulin sensitivity, while a high HOMA-IR value indicates low insulin 
sensitivity and insulin resistance (Bonora E et al., 2002). We found that the HOMA-IR values 
(table 4) were greater in the DIO animals than in the control animals. Mendoza J et al. (2008) 
also reported an increase in the HOMA-IR index as a result of high caloric feeding. The 
biometric and metabolic parameters thus show that the high caloric diet used in this present 
study was of sufficient duration and intensity to induce insulin resistance but not 
hyperglycemia in the DIO animals. 
4.2.2 Glucose uptake 
At a low concentration, deoxy-glucose is taken up by tissues in the body at the same rate as 
glucose (Utriainen T et al., 2000). The deoxy-glucose is, however, not metabolized by the 
cells, therefore it accumulates intra-cellularly (Chadwick WA et al., 2007).  
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Radioactive labelled 2-deoxy-[3H]-D-glucose can thus serve as a tool in measuring glucose 
uptake (Chadwick WA et al., 2007). At basal level the diet had no significant effect on 
glucose uptake, as measured by 2-deoxy-[3H]-D-glucose in cardiomyocytes prepared from 
Langendorff perfused hearts, in the control and DIO animals (figure 12). This result is in 
agreement with those reported by Carroll R et al. (2005), where they demonstrated that basal 
deoxyglucose uptake in 6-8 week diabetic db/db cardiomyocytes was unchanged relative to 
cardiomyocytes from control db/+ mice. Glucose transporter 1 (GLUT1) and glucose 
transporter 4 (GLUT4) are the two main glucose transporters present in cardiomyocytes. At 
basal levels, GLUT4 resides in intracellular, cytoplasmic vesicles, however, during insulin 
stimulation GLUT4 translocates to the plasma membrane where it transports postprandial 
glucose from the extracellular environment into cells (Huang S and Czech MP, 2007). If there 
are no differences in glucose uptake under basal conditions, this would imply that the GLUT1 
transporter concentration in the membranes is similar in the control and the DIO animals. 
 
When the cardiomyocytes were stimulated with 1nM of insulin we found no significant 
differences between the controls and DIO animals. It is possible that this low concentration of 
glucose uptake could not discern the differences between the sensitivity of the cells prepared 
from control vs DIO animals. We did, however, note that the DIO animals had a significantly 
impaired response to insulin, when 10nM and 100nM of insulin was used (figure 12). These 
results are in agreement with what other groups found. Carroll R et al. (2005) demonstrated 
that 10nM of insulin produced a marked stimulation of deoxyglucose uptake by control db/+ 
cardiomyocytes from mice. Huisamen B et al. (2001) also found in two rat models of 
noninsulin-dependent diabetes mellitus (NIDDM) that the insulin-stimulated values of 
glucose uptake were severely impaired in the NIDDM animals compared to the controls.  
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This reduction in glucose uptake in the DIO animals is consistent with peripheral insulin 
resistance as demonstrated by the biometric and metabolic parameters assessed in this study. 
The proposed mechanism for this defect in the DIO animals is that it could be as a result of 
defects located at the level of the glucose transporter (Carroll R et al., 2005). Further, it is 
proposed that there is reduced PKB/Akt activation by insulin, which could also contribute to 
cardiac GLUT-4 translocation defects (Shao J et al., 2000).  
4.2.3 Insulin signalling pathway 
In the insulin signalling pathway, insulin binds to its receptor and activates IRS-1 or IRS-2, 
which then leads to PKB/Akt phosphorylation and activation (Saltiel AR and Pessin JE, 2003; 
Shepherd PR, 2005). The activated PKB/Akt protein is known to directly phosphorylate 
GSK-3α and β  protein on its serine 21/9 residues respectively, thus inhibiting its activity 
(Lawrence JC and Roach PJ, 1997). In the DIO animals we found that total PKB/Akt was 
significantly up-regulated. Phosphorylated PKB/Akt was down-regulated (figure 16) and the 
phospho/total ratio (figure 17) was significantly reduced, indicating that less PKB/Akt was in 
the phosphorylated state in this group under basal conditions. With respect to the GSK-3 
protein, we found no significant differences in total GSK-3β expression levels in the DIO 
animals. The phospho GSK-3β (Ser9) was significantly decreased (figure 22) and the 
phospho/total ratio (figure 23) was also decreased in these DIO animals, however, the latter 
was not significant as a result of the large standard error. These results are consistent with 
what Shulman GI et al. (1990) and Cline GW et al. (1994) found in the muscle tissue from 
type 2 diabetic patients. They reported that GSK-3 is up-regulated, and that this up-regulation 
correlated with decreased glycogen synthase activity and impaired insulin responsiveness. 
The latter is also in agreement with what we found in the biometric and metabolic parameters, 
and it is also consistent with the demonstration of lower insulin-stimulated glucose uptake in 
the DIO animals.  
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4.2.4 The development of myocardial hypertrophy 
In this study we have used ventricular mass, VW/BW ratio, VW/TL ratio, echocardiography, 
protein expression levels, indirect fluorescent microscopy and light microscopy to quantify 
myocardial hypertrophy. In the DIO animals we found an increase in ventricular weight 
(table 4), but the VW/BW ratio (figure 13) was decreased due to the marked increase in body 
mass in the DIO animals. Iyer SN and Katovich MJ (1996) have, however, reported no 
differences in VW/BW ratio in fructose-fed male Sprague-Dawley rats. As a result, VW/TL 
ratio is used in addition to the VW/BW ratio, as the former is regarded as a more accurate and 
stable index for quantifying myocardial hypertrophy, especially when there are fluctuations in 
weight gain, as is evident in our study (Yin FC et al., 1982). Our results show that the 
VW/TL ratio (figure 14) was increased.  
Excess adiposity and body size have been cited as proposed mechanisms of how obesity may 
result in the development of myocardial hypertrophy (Lauer MS et al., 1991; Urbina EM et 
al., 1995; Lorber R et al., 2003). The prevailing hypothesis is that increases in body size 
augment heart size through changes in loading conditions on the heart. The increases in blood 
volume associated with excess adiposity result in an enhanced cardiac output and stroke 
volume (Stoddard MF et al., 1992; Messerli FH et al., 1983). The chronic volume overload 
mediated by obesity results in an increase in LV filling, which in turn leads to chamber 
dilation, and thus enhances preload and myocardial oxygen demand (Peterson LR et al., 
2004). These changes promote cardiomyocyte growth, which is intended to reduce wall stress 
and myocardial oxygen demand by increasing the wall thickness of the heart. If the wall 
thickness does not increase sufficiently in keeping up with the increments in filling volumes, 
LV wall stress may increase (Zarich SW et al., 1991; Alpert MA et al., 1995; Berkalp B et al., 
1995), the consequence potentially being heart failure.  
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Trans-thoracic echocardiography has become one of the most frequently used non-invasive 
tools of assessing LV contractile performance, dimensions and hypertrophy in small animal 
research (Reffelmann T and Kloner RA, 2003). We found no significant differences in LV 
end systolic diameter (ESD), however, we observed a significant increase in LV end diastolic 
diameter (EDD) in the DIO animals (table 5). Messerli et al. (1983) conducted 
echocardiographic analysis on lean and obese patients that were either hypertensive or 
normotensive. Obesity was seen to be associated with an increase in LV diameter, which is 
considered to be indicative of eccentric LV hypertrophy, while hypertension was associated 
with concentric hypertrophy. Fractional shortening (FS), the traditional index of systolic 
function, was used as a parameter of cardiac contractile performance. We found no 
significant differences in FS in the control vs. DIO animals. This result is in agreement with 
that of Rennison JH et al. (2007). They reported that administration of a high saturated fat 
diet did not adversely affect LV contractile function or the progression of LV remodelling. In 
the current study, these findings may be attributed to the fact that too few parameters were 
used to quantify diastolic dysfunction. Alternatively, the ability to observe subtle differences 
in myocardial function may have been limited by the small sample size used (n=6).  
4.2.5 Proteins implicated in the hypertrophic response 
We investigated NFAT-3 and GATA-4 transcription factors as markers of myocardial 
hypertrophy. Calcium signalling mediates the effects of NFAT-3 and GATA-4 proteins, but a 
number of parallel signalling pathways can also regulate these transcription factors. In the 
insulin signalling pathway, GSK-3 phosphorylates NFAT proteins, inhibiting both their 
nuclear localization and DNA-binding activity (Graef IA et al., 1999), hence attenuating the 
hypertrophic response. Additionally, GSK-3 negatively regulates GATA-4’s transcriptional 
activity through N-terminal phosphorylation (Morisco C et al., 2001). This phosphorylation 
subsequently promotes nuclear export of GATA-4.  
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We found that total NFAT-3 expression levels were higher in the cytosolic fraction of both 
the control and the DIO animals (figure 28). Similarly, we found that total GATA-4 
expression levels were lower in the nuclear fraction in both control and DIO animals (figure 
31). We cannot conclude whether these transcription factors were activated to initiate the 
transcription of hypertrophic genes, because the phosphorylation status of these proteins was 
not determined. Despite this, previous data from our laboratory has revealed the presence of 
myocardial hypertrophy in the DIO animals after 16 weeks on the HCD (Du Toit et al., 2005).  
To address the fact that the phosphorylation status of NFAT-3 and GATA-4 was not 
determined, we used indirect immunofluorescence to visualise NFATc3 and GATA-4 
distribution and localisation in cardiomyocytes. These results confirmed the presence of 
myocardial hypertrophy in the DIO animals, as both NFATc3 and GATA-4 were localised in 
the perinuclear area of the cytoplasm (figure 34, 35). However, this phenomenon was only 
seen in some cells. This finding could be attributed to the difficulty of optimising the protocol. 
One of the challenges experienced was cardiomyocyte adherence. We did not culture these 
cells, thus the isolation and staining protocols were all performed in one day, in order to 
avoid contamination. The time frame used to allow these cells to adhere might not have been 
optimal. There are no other studies which use the same model as the one used in this present 
study with which we could confirm the present findings. The findings of this present study 
should, however, not be discredited, as Oliveira RSF et al. (2009) also reported this 
perinuclear localisation. The latter was shown in a knock-in mouse model of heart failure, 
therefore indicating that upon induction of hypertrophic stimuli these transcription factors are 
activated to participate in the transcription of genes which promote hypertrophy.  
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Light microscopy was used to determine cardiomyocyte cell width, another marker of 
myocardial hypertrophy. We found a significant increase in cardiomyocyte cell width in the 
DIO animals (figure 38, 39) indicating concentric hypertrophy. This finding is not what we 
expected to find, as earlier studies suggest that the predominant effect of obesity on LV 
structure is eccentric LV hypertrophy (LV end diastolic diameter increases in proportion to 
wall thickness with no change in relative wall thickness) (Messerli FH et al., 1983; Lauer MS 
et al., 1992; Gottdiener JS et al., 1994; De Simone G et al., 1994). This notion has been 
supported by some recent studies which show the lack of impact of body size on relative wall 
thickness despite an increase in LV mass (Kizer JR et al., 2004; Fox E et al., 2004). 
However, other recent studies indicate that adiposity may be associated with a relatively 
greater increase in LV wall thickness as compared to LV end diastolic diameter, with an 
increased relative wall thickness (concentric LV remodelling and concentric LV hypertrophy) 
being the primary consequence (Mensah GA et al., 1999; Gutin B et al., 1998; Avelar E et 
al., 2007; Woodiwiss AJ et al., 2008). The uncertainty as to whether obesity promotes 
primarily eccentric or concentric LV hypertrophy in these studies may be attributed to the use 
of small study samples (Messerli FH et al., 1983; Gutin B et al., 1998; Wong CY et al., 
2004), non-random recruitment approaches (Messerli FH et al., 1983, De Simone G et al., 
1994) and the assessment of study groups with a limited blood pressure range (Lauer MS et 
al., 1992). All these factors thus show that there are many reasons to explain the uncertainty 
that exists regarding the impact of obesity on LV geometry.  
4.2.6 Lung	  fluid	  content	  
Accumulation of fluid in the lungs is used as an indicator of heart failure; this phenomenon is 
referred to as cardiogenic pulmonary edema (Ware LB and Matthay MA, 2005). Our results 
therefore show that both the diet and the GSK-3 inhibitor treatment did not induce heart 
failure in the animals (figure 15). 
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4.3 Effects of GSK-3 inhibitor treatment  
4.3.1 Biometric and metabolic parameters 
In the current study we treated the animals with the GSK-3 inhibitor CHIR118637 (CT20026) 
supplied by Novartis. This GSK-3 inhibitor inhibits target protein kinases in an ATP 
competitive manner and has been shown to target both the GSK-3α and β isoforms (Cline 
GW et al., 2002; Meijer L et al., 2004). The main findings on the biometric and metabolic 
parameters were as follows: In the control animals, the GSK-3 inhibitor treatment increased 
the body weight, but it had no significant effect on the intraperitoneal fat mass. This increase 
in body weight was also associated with an increase in serum insulin levels and HOMA-IR 
value. However, blood glucose levels were within the normal range (table 4). This data 
indicates that the treatment had an adverse effect on the controls, as these animals show signs 
of whole body insulin resistance with normoglycemia (table 4). However, the effect does not 
seem to be as severe as the effect of the diet. In contrast to the control animals, we found no 
significant differences in body weight or intraperitoneal fat mass in the treated DIO animals. 
These animals displayed normal blood glucose levels, significantly decreased serum insulin 
concentration values and no significant differences in the HOMA-IR index (table 4). The 
results from the treated DIO animals are in agreement with other studies. In a study published 
by Henriksen EJ and Dokken BB (2006), where they also investigated the effects of chronic 
GSK-3 inhibition in prediabetic obese Zucker rats, they found no change in body weight. 
Additionally, they found that fasting plasma glucose was not affected by chronic GSK-3 
inhibitor treatment, however, they did report that the fasting serum insulin levels were 
significantly lowered. In the same study the HOMA-IR values were also significantly 
reduced in these animals. The latter finding is not in agreement with our results, as we found 
no significant differences in the HOMA-IR index.  
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In another independent study Henriksen EJ et al. (2003) also demonstrated in Zucker diabetic 
fatty (ZDF) rat that acute (4h) oral treatment with aminopyrimidine-based GSK-3 inhibitors 
enhanced oral glucose tolerance and whole body insulin sensitivity. All these results are in 
agreement with what we are reporting. Our results are novel in that they indicate that chronic 
GSK-3 inhibitor treatment enhanced fasting whole body insulin sensitivity specifically in the 
DIO animals. However, in the control animals, chronic GSK-3 inhibition may have adverse 
effects, as it may promote insulin resistance. We argue that in the pathological state of insulin 
resistance and downregulation of the phosphorylation of GSK-3, therefore overactive GSK-3, 
inhibition of GSK-3 will normalise signalling and response in these hearts.  However, in the 
control animals with a normal level of expression and phosphorylation of GSK-3 and a 
normal response to insulin, inhibition of GSK-3 will lead to pathology, as indicated by our 
results and discussed in 4.3.3.  
4.3.2 Glucose uptake 
In the control and DIO animals the GSK-3 inhibitor treatment had no significant effect on 
glucose uptake at basal level and upon stimulation with 1nM of insulin (figure 12). In both 
groups a 2-way ANOVA showed a significant overall effect of the treatment upon 
stimulation with 10nM and 100nM of insulin. Additionally, a paired student t-test showed a 
significant increase in glucose uptake upon stimulation with 100nM of insulin in the treated 
DIO animals. The treatment thus normalized glucose uptake in these animals to a similar 
levels as seen in the untreated control animals. This corroborates other studies that showed 
that GSK-3 inhibition promotes glucose uptake into cultured human muscle cells (Nikoulina 
SE et al., 2000), and isolated diabetic rat muscle cells (Ring D et al., 2001). In contrast, Cline 
GW et al. (2002), found no effect of GSK-3 inhibition on insulin stimulation rates of whole 
body glucose disposal in ZDF (fa/fa) rats. 
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4.3.3 Insulin signalling pathway 
In the treated control animals we found no significant differences in total PKB/Akt 
expression, however, phosphorylated PKB/Akt was down-regulated (figure 18) and the 
phospho/total ratio (figure 19) was significantly reduced, indicating that less PKB/Akt was 
phosphorylated in this group. In the treated DIO animals we found no significant differences 
in total, phospho PKB/Akt and the phospho/total ratio (figure 20, 21).  
The lower PKB/Akt activity in the treated control animals ties in well with the conclusion 
that the treatment seemed to induce insulin resistance in these animals. With respect to the 
GSK-3 protein we found a significant decrease in total GSK-3β expression levels in the 
treated control animals. The phospho GSK-3β (Ser9) was, however, significantly increased 
(figure 24) and the phospho/total ratio was also increased (figure 25) in these animals, 
indicating overall inhibition of the kinase. In the treated DIO animals we found no significant 
differences in total GSK-3β expression levels. The phospho GSK-3β (Ser9) was significantly 
decreased (figure 26) and the phospho/total ratio was also decreased (figure 27) in these 
animals. One explanation for the higher level of phosphorylation of GSK-3 in the hearts of 
the treated control animals can be that other kinases are involved besides PKB/Akt. Inhibition 
of GSK-3 will lead to an accumulation of glycogen in these hearts. According to Derave W et 
al. (2000), a high level of glycogen will lead to lower glucose uptake, lower GLUT-4 
translocation as well as lower levels of phosphorylation of PKB/Akt, especially after 
stimulation with insulin. In addition, this increased phosphorylation and inhibition may be 
responsible for the larger cell size in the cardiomyocytes from treated control animals.  
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In a study published by Gao HK et al. (2008) they also showed that the GSK-3 inhibitor 4-
benzyl-2-methyl-1, 2, 4-thiadiazolidine-3, 5-dione (TDZD-8) increased GSK-3 serine-9 
phosphorylation and that this was consistent with inactivation of the kinase. In another study, 
Nikoulina SE et al. (2001), reported that following treatment with GSK-3 inhibitor, PKB/Akt 
expression was unaltered. In the DIO animals we cannot draw any clear conclusions on the 
effects of the inhibitor on PKB/Akt and GSK-3. In contrast, a lower phospho/total ratio of 
GSK-3 was documented in the control animals. This would indicate that the kinase was more 
active in the phase of inhibition. It must be kept in mind that the hearts of the DIO animals 
were insulin resistant before the onset of the treatment regime. 
4.3.4 The development of myocardial hypertrophy 
In the treated animals we found a significant increase in ventricular weight in the treated 
controls, compared to untreated controls, but found no differences in the treated DIO animals, 
compared to untreated DIO (table 4). Additionally, both the VW/BW and VW/TL ratios 
revealed no differences in these groups (figure 13, 14). Yin FC et al. (1982), proposed that 
VW/BW ratio may show no differences as a result of age related fluctuations in weight gain 
and he further proposed that VW/TL ratio be used. These parameters thus indicate that 
chronic GSK-3 inhibition did not obviously promote myocardial hypertrophy in the treated 
DIO rats.  
The echocardiography data also revealed no significant differences in left ventricular 
diameters in systole in both groups, however, we observed a significant increase during 
diastole in the treated control animals (table 5), coinciding with the other documented 
changes in this group. We found no significant differences in FS in any of the groups, 
indicating no effect of the treatment on myocardial function. Tissue Doppler Imaging might 
thus be of use, as it uses more sensitive parameters to quantify both systolic and diastolic 
dysfunction. 
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4.3.5 Proteins implicated in the hypertrophic response 
Regarding the expression of NFAT-3 and GATA-4 transcription factors we found no 
significant differences in total NFAT-3 expression levels in the treated control (figure 29) or 
treated DIO animals (figure 30). However, the significant nuclear export that was observed in 
the untreated animals (figure 28) was absent, indicating that a higher proportion of NFAT-3 
was in the nucleus. We also found no significant differences in total GATA-4 expression 
levels in the treated control (figure 32) and treated DIO animals (figure 33). But again, the 
proportional distribution of cytosolic vs. nuclear protein was in favour of a higher proportion 
of the protein in the nucleus. Total expression levels of these proteins were measured, not 
their phosphorylation status.  
Indirect immunofluorescence was also used to visualise NFATc3 and GATA-4 distribution 
and localisation in cardiomyocytes. These results confirmed the presence of myocardial 
hypertrophy both in the treated control and treated DIO animals as both NFATc3 and GATA-
4 were localised in the perinuclear area of the cytoplasm (figure 36, 37). Interestingly, this 
phenomenon was only seen in some cells. Once again this could be as a result of the time 
frame used to allow these cells to adhere. This might not have been optimal. Unfortunately, 
there are no other studies which used the same model and treatment regimen as the one used 
in this present study with which we could confirm our findings. 
Light microscopy was used to determine cardiomyocyte cell width, a marker of myocardial 
hypertrophy. The GSK-3 inhibitor treatment increased cardiomyocyte cell width significantly 
in the controls, however, in the DIO animals it significantly decreased the cell width (figure 
38, 39). This would imply that the treated DIO animals had eccentric hypertrophy. There are 
no other studies which use the same model and treatment regiment as the one used in this 
present study with which we could compare our results to.   
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5 CHAPTER 5: CONCLUSION 
 
 
The primary aims of the current study were to document the progression of myocardial 
hypertrophy in a rat model of pre-diabetes and insulin resistance, and to assess the role of 
inhibition of the GSK-3 protein on this hypertrophic response. We successfully showed that 
the high caloric diet promotes the development of insulin resistance and myocardial 
hypertrophy. We also showed that this insulin resistant state was accompanied by a disruption 
of the insulin signalling pathway, characterized by alterations in involved proteins, such as 
PKB/Akt and GSK-3. Regarding the effect of the inhibitor, we observed signs of insulin 
resistance in control animals, while inhibition of GSK-3 improved the glycemic control in the 
DIO animals. In addition, treatment of normal control rats with the GSK-3 inhibitor resulted 
in clear signs of the beginning of myocardial hypertrophy, but did not exacerbate the 
hypertrophic state in the pre-diabetic animals.  
In view of the fact that GSK-3 inhibitors are currently developed for clinical utilization in 
disease states not associated with obesity, insulin resistance or cardiovascular disease (e.g. 
muscle hypertrophy, Alzheimer’s disease, certain types of cancer and bipolar- and mood 
disorders, as discussed on page 31), the results from this study is deemed very important as it 
highlights the possible side effects of such treatment. Interventions targeting protein kinases 
should therefore be subject to further investigations to establish unknown interactions.  
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Limitations of this study: 
There are many pathways implicated in the development of myocardial hypertrophy, and the 
current study was limited to focus on the insulin signalling pathway, especially on the role of 
the GSK-3 protein. Unfortunately, a limited amount of inhibitor for in vivo studies was 
supplied, therefore we were unable to investigate the effect of GSK-3 protein on downstream 
substrates.  
5.1 Future studies 
To confirm the effectiveness of the inhibitor in vivo, we will investigate the expression and 
phosphorylation of glycogen synthase protein. Glycogen synthase is a downstream substrate 
of GSK-3, which plays a role in regulation of glycogen synthesis (MacAulay et al., 2005). 
We expect to find decreased insulin stimulated phosphorylation. Since we cannot exclude the 
participation of other pathways we would like to look at key proteins in the Wnt pathway that 
promote hypertrophy. We also wish to determine the phosphorylation status of NFAT-3 and 
GATA-4. We would also like to perform Tissue Doppler echocardiography, as this method 
has been shown to be more sensitive and will allow us to determine more specific parameters 
for systolic and diastolic dysfunction. Additionally we would like to increase the sample 
number, as our results show that there are subtle differences, and the small sample number 
might have been a confounding factor for observing any differences. 
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